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Nosocomial transmission of drug resistant tuberculosis is well-documented in South Africa. The level 
of risk varies by patient population and effectiveness of M.tb infection control measures. The risk is 
higher in places where large numbers of infectious M.tb patients are being treated, particularly in the 
absence of other infection control measures such as respiratory protection. Globalization has led to the 
exchange and circulation of the various strains worldwide, leading to greater global diversity of M.tb 
strains. This ultimately increased the risk of individuals being infected with more than one strain at a 
time ie; having mixed infection 
Methodology 
In this study, we investigated the extent of transmission of drug resistant M. tuberculosis between 
patients hospitalized in a specialized TB hospital. The study was carried out at the FOSA TB hospital, 
Durban, South Africa. Genotyping was performed using IS6110-RFLP and spoligotyping.  
Results  
A total of 52 patients were recruited, from which 28 isolates were successfully cultured and 
genotyped. Cluster analysis of the isolated genotypes suggests nosocomial transmission of drug 
resistant strains amongst the in-patients. A majority of the strains found among the patients belonged 
to the F15/LAM4/KZN family (64%), followed by three clusters of formerly uncharacterised strains 
which were named Unique I, II and III. Only one of the drug resistant isolates belonged to the Beijing 
family of strains. Several locations and activities were identified where transmission could potentially 
have occurred, but this could not be done for individual patients   
Conclusion 
Implementation of rapid diagnostic testing for drug-resistant TB and redesign of healthcare facilities, 
to minimize congregate spaces, are critical elements that should be included in TB infection control 







CHAPTER 1: INTRODUCTION 
Infections with Mycobacterium tuberculosis (M.tb) account for high rates of morbidity and mortality 
worldwide (Cox et al., 2010). The organism has the ability to persist in the human host in a dormant 
state for prolonged periods of time in the face of an active immune response. Progression from initial 
infection to disease is influenced by the balance between bacillary persistence and the immune system 
impairment (Ulrichs and Kaufmann, 2002, Kaufmann and Schaible, 2005, Mlambo, 2011). The 
causes of an impaired host response include among others, age, malnutrition, excessive use of 
steroids, uncontrolled diabetes mellitus, renal failure, underlying malignant disease, chemotherapy as 
well as human immunodeficiency virus (HIV) infection. All of these factors can result in the 
reactivation of dormant bacilli, resulting in clinical manifestations of tuberculosis (Mlambo, 2011). 
The development of drug resistance among circulating tuberculosis (TB) strains continues to pose a 
challenge to health systems worldwide. Multidrug resistant (MDR-TB) is defined as, TB caused by 
M.tb resistant to both isoniazid (INH) and rifampicin (RIF), the two most powerful first-line anti-TB 
drugs (Chakraborty et al., 2010, Marahatta, 2010, Magana-Arachchi, 2013). Extensively drug-
resistant  (XDR-TB) is MDR-TB in which the causative agent is additionally resistant to any 
fluoroquinolone, and at least one of the three injectable second-line drugs (viz: capreomycin, 
kanamycin and amikacin) (Chakraborty et al., 2010, Marahatta, 2010, Klopper et al., 2013).  
A South African countrywide survey, in 2002, revealed that 1.8% of all new TB patients and 6.7 % of 
previously treated TB patients had MDR-TB (Weyer et al., 2004). This finding translated to an 
estimated annual case load of 13 000 MDR-TB cases, which placed South Africa (SA) fourth after 
China, India and the Russian Federation (WHO, 2008). However, this case load may be an 
underestimation due to poor case finding and reporting (Cox et al., 2010).  
Gandhi et al., (2006) reported a prevalence of 14% MDR-TB among study patients, 24% of which 
was found to have XDR-TB in Tugela Ferry, Umzinyathi District of South Africa. Additionally, they 
reported that all the XDR-TB infected patients were HIV-seropositive. The mortality in the latter was 
98%  with a median survival time from sputum collection to death of 16 days (Gandhi et al., 2006). It 
is also worth noting that the majority of these patients had not been previously treated for TB, which 
implies that they were newly infected with a TB strain with the XDR resistance profile. (Gandhi et al., 
2006, Grobusch, 2010). Furthermore, genotyping of the collected isolates showed that 39 of 46 (85%) 
patients with XDR-TB were infected with the same strain, suggesting possible nosocomial 
transmission (Gandhi et al., 2006, Grobusch, 2010).  
Adding to the challenge of M.tb transmission, hospitals across SA routinely discharge patients, if all 
available treatment options have been exhausted (Kellend, 2014). Premature release of these patients 
may be due to lack of bed space in designated tuberculosis hospitals, and the scarcity of alternative 
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long-term residential and palliative care facilities, resulting in community-based spread of the disease 
(Kellend, 2014).  
There have been reports showing the occurrence of polyclonal or “mixed” infections within a single 
individual (Cohen et al., 2012). The prevalence of mixed infections is not well documented (Mbabazi 
and Ouifki, 2010). Some studies have shown that it ranges between 2.3% and 75% in patients with 
active TB (van Rie et al., 1999, Richardson et al., 2002). An individual may have active and latent 
forms of the disease caused by different strains concurrently (Mbabazi and Ouifki, 2010). This has 
resulted in a paradigm shift in our understanding of the epidemiology of TB and may have important 
consequences on the implementation of interventions (e.g. treatment of latent infection), and on the 
prospect of developing effective preventative or therapeutic vaccines (Cohen et al., 2011). 
Infection prevention measures for TB in  healthcare facilities are seldom prioritized. This results in 
unrecognized nosocomial transmission (Escombe et al., 2010).  Long length-of-stay, crowded 
congregate wards, poor infection prevention practices, and high prevalence of HIV infection create 
the ideal conditions for nosocomial transmission of M.tb. (Gandhi et al., 2013). Furthermore, with 
little being known about the scope of mixed infections despite advances in strain genotyping, this 
greatly impacts on the interpretation of epidemiological data and subsequent treatment of patients 
(Shamputa et al., 2006). 
The aim of this study was to determine the extent of cross infection amongst patients admitted at the 
FOSA TB hospital, in KwaZulu-Natal, South Africa and to ascertain possible transmission chains 
between patients. This hospital is earmarked for the care of patients with MDR- and XDR-TB. 
The objectives of the study were:  
1. To determine patients’ previous history of TB and current symptoms of TB 
2. To perform daily mycobacterium culture on sputum specimens from all patients admitted to 
the designated wards during the 2-week study period followed by specimens collected at 
month 1 and month 2 post-recruitment 
3. To perform susceptibility tests on all M.tb isolates 
4. To genotype the M.tb isolates using IS6110-RFLP and spoligotyping 
5. To link patient bed proximity and socialisation patterns during hospital stay to subsequent 





CHAPTER 2: LITERATURE REVIEW 
2.1. Global burden of TB  
In 2014 it was estimated that there were 9.6 million incident cases of M.tb globally, up from 8.6 
million in 2012 (WHO, 2015).  The highest number of cases occurred in Asia (58%) and Africa 
(28%); smaller proportions of new cases occurred in India (23%), Indonesia (10%) and China (10%) 
regions. The 22 high burden countries (including South Africa),  accounted for 80% of all estimated 
incident cases worldwide (WHO, 2014). 
South Africa was found to be one of the countries with the highest burden of M.tb infections, where 
an estimated incidence of 450,000 cases of active TB was reported in 2013 (WHO, 2014).  Of a 
population of approximately 50 million, almost 1% develops active TB each year. WHO estimated 
that, of the 450,000 incident cases, 270,000 (60%) were co-infected with HIV (WHO, 2014).  
The province of KwaZulu-Natal (KZN) in SA, is the epicentre of the HIV and TB co-epidemic 
(Kasprowicz et al., 2011), and is also the province with the highest prevalence of drug-resistant TB 
(Shenoi et al., 2009, Cohen et al., 2015). Over 100,000 cases of TB are reported each year from this 
province alone (WHO, 2014). In 2006, the largest outbreak of XDR-TB was reported from KZN, SA 
(Gandhi et al., 2006, Cooke et al., 2011, Gandhi et al., 2012, Gandhi et al., 2013).  
 
2.2. The TB bacillus 
M.tb, the causative agent of TB in humans, is a non-motile rod-shaped bacterium. It belongs to the 
order Actinomycetales, family Mycobacteriaceae, and genus Mycobacterium (Ducati et al., 2006). It 
is an acid fast bacillus, classified as an obligate aerobe. The microbe’s width and length vary from 0.3 
to 0.6 µm and 1-5 µm, respectively. It is characterized by a thick and complex lipid rich cell wall with 
components which are associated with its pathogenesis (Reed et al., 2004, Zuber et al., 2008) and 
considerably slow growth (Ducati et al., 2006).  
For many years M.tb has been described as a strict aerobic, facultative intracellular pathogen with 
cells of the macrophage lineage as its primary target cell. The organism enters these cells by adhesion 
to the C1 receptor on the cell surface. The resulting endocytosis is incomplete as it does not result in 
fusion with a lysosome and therefore killing of the bacterium does not occur. More recently, it was 
shown that alveolar epithelial cells are also important target cells. In addition, there is substantial 
evidence that the organism is not a strict aerobe but can also metabolise and multiply under anaerobic 
conditions (Harakiram P, PhD thesis, UKZN, 2008).   
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Another point, thought for decennia to be true, is that close contact of long duration is needed for 
transmission to occur effectively. Close contact, which means within the distance that allows for 
infected droplet nuclei from a patient to reach an uninfected person, is still essential. However, it has 
been shown as early as mid-1990s by comparing genotyping results with classic epidemiology that 
casual contact is sufficient (Wilkinson D, PhD Thesis, University of Natal, 1997). This was followed 
by several other studies confirming this observation (Dodd et al, 2016). 
 
 
Figure 2.1: Mycobacterium tuberculosis revealed with acid-fast Ziehl-Neelsen stain (1000x).  
Resistance development in M.tb is largely due to mutational events affecting the genes coding for 
drug target molecules. The reason for this is that exchange of resistance gene carrying genetic 
elements like plasmids cannot occur due to the cell wall structure of mycobacteria. In addition, no 
transduction takes place between mycobacteria and species from other genera since only 
mycobacteriophages do infect mycobacterial species with limited host range for each of them within 
the family of Mycobacteriaeceae. Since the chances that more than one mutation occurs in the same 
bacterial cell, it was thought that the multidrug approach which has been practiced for many years 
would prevent resistance to multiple drugs to occur. However, since the mid 1990’s strains resistant to 





2.3. Multidrug resistant tuberculosis  
The emergence and spread of MDR-TB continues to threaten TB control globally (Corbett et al., 
2003, Alexander and De, 2007, Cox et al., 2010). In 2007, global TB data from 198 countries reported 
an estimated 0.5 million cases of MDR-TB, with 27 countries accounting for 85% of all cases 
(Magana-Arachchi, 2013). India, China, the Russian Federation, SA and Bangladesh were ranked the 
highest in terms of total numbers of MDR-TB cases (WHO, 2009). The global burden of MDR-TB is 
thought to be much higher than the current estimates (Chakraborty et al., 2010, WHO, 2014). 
South Africa’s estimated incidence of TB has risen from 317 to 1000 per 100 000 between 1995 and 
2012 (Bantubani et al., 2014). The spread of drug-resistant TB within SA constitutes an additional 
challenge in control of the disease (Bantubani et al., 2014) and has resulted in a fifth place among 
countries with the highest global incidence of MDR-TB after China, India, Russian Federation, and 
Pakistan (Bantubani et al., 2014). The urgency in addressing drug-resistance in a high HIV prevalence 
setting was underscored by the report of an outbreak of XDR-TB  in Tugela Ferry centred in and 
around the Church of Scotland Hospital (CoSH) in the Msinga sub-District of KZN (Gandhi et al., 
2006). This report documented the largest outbreak of XDR-TB with 6% of the study population 
harbouring XDR-TB strains; additionally, all of the latter were also HIV-sero-positive.  This focused 
global attention, not only to the drug-resistance problem in SA, but also to worldwide resistance 
(Gandhi et al., 2006, Ioerger et al., 2009). Furthermore, XDR-TB has been reported throughout SA 
(Karim et al., 2009), in neighbouring sub-Saharan countries and in 58 countries worldwide (Bwanga 
et al., 2010, WHO, 2010).  
In order to determine the extent of the drug resistance, mixed infections, as well as nosocomial  
infections, molecular biology techniques have been applied to determine the genetic fingerprint of the 
clinical isolates. Applying such techniques, a study by Pillay and Sturm (2010) revealed that the 
strains prevalent in  Tugela Ferry were of the F15/LAM4/KZN genotype (Pillay and Sturm, 2010). 
Furthermore, retrospective studies on the evolution of this genotype in the province showed that this 
M.tb strain type has been responsible for cases of MDR-TB since 1994 and XDR-TB cases from 2001 
(Pillay and Sturm, 2010). XDR-TB has been reported in all of the country’s provinces and has been 
shown to belong to various strain families (Mlambo et al., 2008, Gandhi et al., 2014). 
2.4. Treatment of tuberculosis 
The dawn of anti-TB chemotherapy was in 1944 with the discovery of streptomycin (STR), 
followed by the discovery of para-aminosalicyclic (PAS) in 1946 (Daniel, 2006, Zhang and 
Yew, 2009). A study done by Fleury (1951), comparing the efficacy of STR and PAS when 
used alone and in combination, showed that combined therapy was more effective (Wada, 
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2007). This provided initial evidence for the multidrug approach in the management of TB. 
The addition of isoniazid (INH) and pyrazinamide (PZA) in 1952 to the treatment regimen 
improved treatment outcomes with cure rates approximating 100% (MRC, 1950, Jawahar, 
2004). The duration of treatment however, was still lengthy (18 to 24 months). With the introduction 
of rifampicin (RIF) in the early 1960s, the treatment duration of TB was sequentially decreased to the 
currently recommended duration of 6 months for uncomplicated drug susceptible TB (Wada, 2007).  
The internationally recommended TB chemotherapy strategy known as Directly Observed Treatment 
Short-course (DOTS) is aimed at completely eliminating active and dormant bacilli, and involves two 
phases of treatment using first-line anti-TB drugs (Narita et al., 2002). The initial (intensive) phase 
comprises the use of INH, RIF, ethambutol (EMB) and PZA for 2 months, followed by 4 months 
continuous phase treatment using INH and RIF only (Mitchison, 2005). Despite the effectiveness of 
anti-TB drugs in the management of the disease, the burden of disease remains a global problem and 
is exacerbated by the emergence and spread of drug-resistant strains (Mlambo, 2011). While 
infections with drug-sensitive M.tb can be effectively treated with first-line drugs, the treatment of 
infection with MDR-TB strains remains a challenge with poor treatment outcomes. The long 
treatment duration can significantly increase the risk of patient non-compliance and increases the cost 
of treatment significantly (WHO, 2008, Mlambo, 2011). The current recommended standardized 
regimen for MDR-TB treatment comprises 4 months intensive phase using kanamycin (KM), 
ofloxacin (OFX), ETH, PZA, EMB or Terizidone (TZ), followed by a continuous phase for 12 to 18 
months comprising ETH, OFX, EMB or TZ (Mlambo, 2011).  
The emergence of XDR-TB strains of M.tb has further complicated the treatment regimens for 
tuberculosis. Treatment of XDR-TB cases is associated with even poorer outcomes than MDR-TB, 
especially in patients co-infected with HIV resulting in high mortality (Gandhi et al., 2006, Gandhi et 
al., 2010). 
     
2.5. Transmission 
M.tb is spread from person to person through the air by droplet nuclei which are produced when 
persons with pulmonary or laryngeal TB cough, sneeze, speak or sing (Frieden et al., 2003). Droplet 
nuclei can also be generated through sputum induction, during inhalation therapy, and through 
processing of laboratory specimens (Tang et al., 2006, Selekman, 2006, Mlambo, 2011). Due to their 
small size, droplet nuclei can remain airborne for minutes to hours after expectoration (Nardell, 2004). 
When inhaled, droplet nuclei are carried down the bronchial tree and implant in respiratory 
bronchioles or alveoli in the lungs. Whether or not an inhaled tubercle bacillus establishes an infection 
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in the lung depends on both bacterial virulence and the strength of the immune system (Frieden et al., 
2003). 
Transmission of M.tb is highest in overcrowded and poorly-ventilated environments such as prisons, 
clinics and hospitals, which have been reported to have higher incidence rates compared to the general 
population (Ramtahal, 2011).  
2.5.1. Nosocomial transmission 
TB has long been recognized as a potential occupational hazard by the medical community. In the 
mid-1980s, only a few institutions were prepared for the changing epidemiology of the disease, which 
led to the resurgence of TB  (Raviglione et al., 1993). Infection control measures were put in place to 
reduce transmission, however, as the incidence of TB, and with that the risk of occupational exposure 
and infection, declined less attention was paid to infection control practices (Menzies et al., 1995). In 
the 1990s, outbreaks of the disease highlighted the risk of nosocomial transmission of TB and risks 
for health care workers, highlighting again the importance of effective infection-control measures 
(Reichman and Hershfield, 2000).  
Since then, nosocomial transmission has been well documented (Dooley et al., 1992, Pearson et al., 
1992, Gandhi et al., 2006), and factors that facilitate nosocomial transmission of TB have been 
identified (Table 2.1) (Reichman and Hershfield, 2000). The level of risk varies by patient population 
and effectiveness of M.tb infection control measures. The risk is higher in places where large numbers 
of infectious M.tb patients are being treated, particularly in the absence of other infection control 
measures such as respiratory protection (CDC, 2005).  
 
Table 2.1: Factors facilitating nosocomial transmission of TB. 
1. Inefficient infection-control procedures 
 Delay in ordering diagnostic tests 
 Clustering of patients  
 Failure to isolate patients with active pulmonary disease 
 Failure to employ appropriate PPE 
2. Laboratory delays in identification and susceptibility testing of M.tb isolates 
3. Inadequate isolation facilities and engineering controls 
 Lack of isolation rooms 
 Recirculation of air from isolation rooms to other parts of the hospital 
4. Delayed initiation of effective anti-TB therapy 




In previous outbreaks investigated by the Centers for Disease Control and Prevention (CDC), the lack 
of adequate procedures to identify patients with possible TB, and the failure to isolate such patients 
immediately once TB was suspected, was highlighted as a major factor responsible for nosocomial 
transmission of the disease (McGowan, 1995). Other factors have included fraternization of suspected 
M.tb patients with patients at increased risk for TB infection eg: immune compromised HIV-infected 
patients. Inadequate laboratory facilities and far from robust rapid diagnostics and susceptibility 
testing for TB also lead to a delay in initiation of anti-TB therapy, which allows for prolonged 
infectivity and increased risk of transmission of M.tb (Jarvis, 1995). 
2.5.2. Prevention of nosocomial transmission of TB 
Nosocomial spread of M.tb can be prevented by a combination of administrative, infrastructural and 
engineering controls, as well as personal protective equipment for healthcare workers and patients 
(Table 2.2). 
 







designed to reduce exposure 
to aerosols and thus reduce 
the risk of transmission, 
infection and disease.  
Fundamental facilities, 
practices, or equipment that 
reduces the concentration of 
infectious bacilli in the 
environment. 
Protection of personnel 
working in areas with 
contaminated air. 
Examples: 
Rapid identification of high-
risk patients and removal to 
a separate area. 
Rapid screening policies. 
Isolation of patients with 
suspected or confirmed TB. 
Examples: 











The implementation of the above-mentioned measures presents major difficulties, especially in 
resource-limited settings (Whitelaw, 2011, Shenoi et al., 2012). A systematic approach used to assess 
and analyse the effectiveness of a health care facility’s existing control programs, strengthens them 
and curbs nosocomial transmission of M.tb (Pearson et al., 1992, Pillay and Sturm, 2010). 
 
2.6. Dedicated MDR-TB hospitals in SA 
With drug resistant TB on the rise, SA has insufficient infrastructure to cope with the ongoing 
epidemic. In existing dedicated MDR-TB hospitals infrastructure constraints remain an obstacle to 
safe health service delivery. This is due to the fact that the buildings used for housing TB patients 
have been built before MDR-TB developed. At that time cross infection could not occur because the 
treatment regimen a patient was on protected against this. Other key issues include funding and 
staffing constraints and lack of bed space for the increasing number of infected TB patients. Ideally, 
infected patients should be housed in isolation rooms to reduce the opportunity of cross-infection. 
Research has shown that patients housed in multi-bed units are often cross-infected with different 
strains of TB (Ulrich et al., 2008, Sissolak et al., 2011) resulting in increased treatment costs and an 
increase in the length of stay.  
The treatment policy in SA requires the hospitalization of drug-resistant patients until they have two 
consecutive negative TB cultures at least a month apart (NDoH, 2007). The increasing infection rate 
and improved case finding have led to an increasing number of patients who require hospitalization 
(Sissolak et al., 2011). Meeting the accommodation needs for the patients infected with a drug 
resistant strain provide a significant challenge which has resulted in existing TB hospitals being used 
as alternative accommodation to house the increasing number of drug-resistant patients. Most of the 
existing TB hospitals were designed with large open wards which are suitable for drug-susceptible 
TB, but are not appropriate for patients with drug-resistant TB (Parsons et al., 2010).  
In 2010, the Department of Health began decentralising treatment for drug resistant TB from 
specialised hospitals to facilities closer to patients living areas. This increased the bed availability for 
MDR-TB patients and decreased the obstacles for family members to visit patients (NDoH, 2010). 
Decentralization has allowed for earlier treatment initiation resulting in shorter hospital stays, and 
earlier release into controlled out-patient treatment facilities closer to their homes (Sinanovic et al., 
2015).   
There are currently 9 MDR-TB decentralised management units and 17 MDR-TB satellite sites, found 
in 8 districts (Ugu, eThekwini, Zululand, Harry Gwala, Umkhanyakude, UThungulu, 
UMgungundlovu and Umzinyathi) in the KwaZulu-Natal Province. 
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Infection prevention and control (IPC) for TB in SA  is the responsibility of the individual healthcare 
facilities (Sissolak et al., 2011). As mentioned above, TB-IPC is based on a three-level hierarchy of 
controls, including administrative, environmental, and respiratory protection (Sissolak et al., 2011). 
Sissolak et al., (2011) discovered a total lack of isolation facilities in public sector hospitals in SA 
(Sissolak et al., 2011), in 2011. Furthermore, Tshitangano et al., (2013) found that IPC interventions, 
in SA, were still not aligned to the WHO policy on TB infection control in healthcare facilities. The 
researchers also reported the lack of TB infection control plans in these hospitals (Tshitangano et al., 
2013). This greatly contributes to nosocomial transmission amongst patients in SA (Sissolak et al., 
2011, Gandhi et al., 2013). Nurses in Port Elizabeth’s Joseph Pearson TB hospital reported that MDR-
TB patients were contracting XDR-TB strains even though they were housed in designated wards 
(Sissolak et al., 2011). TB-IPC needs to be strengthened and regularly monitored in South African 
healthcare facilities in an attempt to curb the drug-resistant TB epidemic. 
 
2.7. Mixed strain Infections 
While it was originally assumed that M.tb was a homogenous species, with the advent of genotyping 
methodologies, different strains were reported from different geographic regions (Mbabazi and 
Ouifki, 2010). Globalization has led to the exchange and circulation of the various strains worldwide, 
leading to greater global diversity of M.tb strains (Beyers et al., 1996). This ultimately increased the 
risk of individuals being infected with more than one strain at a time ie; having mixed infection 
(Mbabazi and Ouifki, 2010).  
Genetic heterogeneity of M.tb within a host may arise by one of two mechanisms: (i) intra-host 
diversification following a single infection event, or (ii) sequential acquisition of M.tb from different 
persons resulting in a mixed infection with more than one strain (Cohen et al., 2011). The clinical 
consequences of intra-host diversity are most obvious when manifesting as subpopulations of bacteria 
with resistance to anti-TB antibiotics, either reflecting acquired drug resistance or transmitted drug 
resistance (Cohen et al., 2011). The intra-host competition between strains may influence the clinical 
outcomes for co-infected patients (van Rie et al., 2005b) because individuals can be simultaneously 
infected by strains with different phenotypic characteristics (e.g. growth rates, drug resistance) (Cohen 
et al., 2011).  
Using molecular genotyping methods, the frequency of mixed infection was shown to range from 
2.8% to 19% in countries like Malawi, China, Uganda, Taiwan, Georgia, Central Asia and SA 
(Warren et al., 2004, Shamputa et al., 2006, Hanekom et al., 2013), in 2013. As mentioned 
previously, the prevalence of mixed infections among the various M.tb cohorts is not well 
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documented (Mbabazi and Ouifki, 2010). Some studies have shown that it ranges between 2.3% and 
75% in individuals with active TB (van Rie et al., 1999, Richardson et al., 2002). However, its 
prevalence in the total population is unknown. The difficulty in determining the prevalence of mixed 
infections is due to the deficiencies associated with current diagnostic tests. 
2.7.1. Detection of mixed infections 
The diversity present within M.tb isolates has generated a new appreciation for this genetically 
conserved bacterial species (Brown et al., 2010, Cohen et al., 2010). Molecular genotyping 
applications, such as restriction fragment length polymorphism (RFLP), using the IS6110 insertion 
sequence, spacer oligonucleotide (spoligo) typing, as well as mycobacterial interspersed repetitive-
unit-variable-number tandem-repeat (MIRU-VNTR) typing, have been used to identify transmission 
chains (Daley et al., 1992, Alland et al., 1994), to classify strains into families and lineages (Allix-
Beguec et al., 2008, Comas et al., 2009) and to detect the presence of intra-host genetic heterogeneity 
(Warren et al., 2004, Shamputa et al., 2006). 
Molecular epidemiological studies have been able to identify individuals with repeated episodes of 
disease due to re-infection (Richardson et al., 2002, Small et al., 1993, Chiang and Riley, 2005). The 
data confirm previously reported findings, suggesting previous exposure or disease does not confer 
protection against subsequent re-infection (Canetti et al., 1972, van Rie et al., 2005a, Andrews et al., 
2012). This has resulted in a paradigm shift in our understanding of the epidemiology of TB and may 
have important implications for the implementation of interventions (i.e. treatment of latent infection), 
and for the prospect of developing effective preventative or therapeutic vaccines (Cohen et al., 2011). 
 
2.8. Genotyping of Mycobacterium tuberculosis 
Genotyping of M.tb has greatly improved the study of TB epidemiology (Zaczek et al., 2013). It is 
essential in the identification of strains circulating within a population, making it possible to monitor 
prevalent strains and their potential mutations (Gori et al., 2005). Identification of epidemiologically 
linked M.tb strains helps to reveal the source of infection, to trace the transmission routes of various 
strains, and to determine the risk factors for M.tb transmission in a community (Zaczek et al., 2013). 
This may assist coordinators of TB-control programs to direct and evaluate their programme activities 
(Miller et al., 2002). The gold standard for M.tb genotyping is RFLP using IS6110 as a marker, but 
other molecular typing techniques such as spoligotyping and MIRU-VNTR, could be used as adjuncts 
in select circumstances (Cohn and O'Brien, 1998).  
2.8.1. IS6110-RFLP  
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IS6110-RFLP analysis relies on the determination of the number of copies and location of the IS6110 
elements on the chromosome (McEvoy et al., 2007). This insertion sequence was first recognized by 
van Embden and colleagues in the 1990s (van Embden et al., 1993). The IS6110 sequence belongs to 
the IS3 family and is 1.355-kilo base pairs long. It is found in species within the M.tb complex, and in 
most members of the complex, the sequence is present as multiple copies. The exception is 
Mycobacterium bovis which usually contains one copy (Jagielski et al., 2014). The IS6110-RFLP 
technique is considered as a reference standard for strain differentiation in molecular epidemiological 
studies, and has been widely used for the identification and investigation of outbreaks, the 
identification of laboratory cross-contamination, and distinction between re-infection and relapse 
(McEvoy et al., 2007). The method includes digestion of genomic DNA with PvuII restriction enzyme 
that cleaves the IS6110 sequence only once, generating DNA fragments that are separated through gel 
electrophoresis. The separated products are then transferred onto a membrane, and hybridized with a 
peroxidise-labelled probe complementary to part of the 3’-end of the IS6110 sequence (Jagielski et 
al., 2014). The method is highly discriminatory and reproducible. However, the method has several 
disadvantages that limit its use in routine practice: 1) poor discriminatory power when applied to 
isolates with a low IS6110 copy number, 2) labour-intensive, 3) requires weeks of incubation to 
obtain sufficient quantities of high-quality DNA, and lastly, 4) generates band patterns that may be 
difficult to share between laboratories (Sougakoff, 2011). 
Despite the limitations, IS6110-RFLP method remains one of the most commonly used approaches 
for M.tb typing and has long been considered the gold standard technique in molecular 
epidemiological investigations of TB (Jagielski et al., 2014). Its main advantage is high 
reproducibility and high discrimination between organisms. 
 
2.8.2. Spoligotyping 
Spoligotyping is based on the amplification and detection of the presence, or absence, of non-
repetitive sequences called spacers found between direct repeat elements in the clustered regularly 
interspaced short palindromic repeats (CRISPR) region (van Embden et al., 2000, Kato-Maeda et al., 
2011). Regularly interspaced short palindromic repeats (CRISPRs) can be used for both epidemiology 
and evolutionary analysis of M.tb (van Embden et al., 2000). The entire direct repeat locus is 
amplified by Polymerase Chain Reaction (PCR (Jagielski et al., 2014). The PCR products are then 
hybridized onto a membrane with 43 covalently bound synthetic oligonucleotides representing the 
polymorphic spacers identified in M.tb H37Rv (spacers 1-19, 22-32, and 37-43) as well as M. bovis 
BCG (spacers 20-21 and 33-36) (Jagielski et al., 2014). The hybridization signals are then detected by 
chemiluminescence through biotin labelling of the PCR products (one of the primers is biotinylated) 
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and a streptavidin-peroxidase conjugate system and then visualised by autoradiography (Jagielski et 
al., 2014). Individual strains are differentiated by the number of the spacers that are missing from the 
complete 43-spacer set (Kamerbeek et al., 1997). As opposed to IS6110-RFLP, spoligotyping is based 
on PCR amplification which requires small amounts of DNA thus bypassing the need for a large 
amount of isolates (Sougakoff, 2011). It is a relatively simple, cost effective, and high-throughput 
method, whose results are accurate, reproducible and are obtained in up to 2 days (Jagielski et al., 
2014). Furthermore, given the binary format of the data, the spoligotyping results can easily be 
interpreted, computerized, and compared between different laboratories using the international 
spoligotyping database (SpolDB4) which was released in 2006 and is accessible online (Jagielski et 
al., 2014).  
The signatures given by the 43 spacer-spoligotyping patterns have been used to define strain families 
and a description of the circulating genotypes of tubercle bacilli worldwide (Brudey et al., 2006). As 
compared with the other molecular methods, the main limitation of spoligotyping is its limited 
discriminatory power, particularly in some lineages such as the Beijing strains, where nearly all share 
a single spoligotype (Sougakoff, 2011). The discriminatory power of spoligotyping was reported to be 
lower than IS6110-RFLP (Kremer et al., 1999). The reason for the limited discriminatory capacity of 
the spoligotyping method is due to the fact that it targets only a single genetic locus, covering less 
than 0.1% of the M.tb complex genome (Jagielski et al., 2014). Nevertheless, spoligotyping can be 
effectively used for the differentiation of M.tb strains with low IS6110 copy numbers (Jagielski et al., 
2014). 
2.8.3. MIRU-VNTR 
Variable numbers of tandem repeats (VNTR) analysis is a powerful method that can provide adequate 
discrimination of M.tb strains, in terms of both identification of genetic lineages and estimation of 
transmission (Supply et al., 2000). The method is PCR-based, relies on the analysis of tandem repeats 
present in 41 genetic elements (called mycobacterial interspersed repetitive units [MIRUs] scattered 
throughout the M.tb genome, with a variable number of copies of the repeat unit in each locus. MIRU-
VNTR analysis involves PCR amplification of a specific MIRU locus, followed by determination of 
the sizes of the amplicons by gel electrophoresis or, after running multiplex PCRs, on an automated, 
fluorescence-based sequencer (Jagielski et al., 2014). Since the lengths of the repeat units are known, 
the calculated sizes reflect the numbers of the amplified MIRU copies. The final result is a multi-digit 
numerical code (MIRU-VNTR code) corresponding to the repeat number at each analysed locus 
(Jagielski et al., 2014). This coding system allows the results to be readily compared across 
laboratories worldwide and facilitates the data to be deposited in the global databases via the internet 
for large-scale epidemiological and population genetic studies (Jagielski et al., 2014).  
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The MIRU-VNTR method is an efficient and reliable typing system, whose discriminatory capacity 
approximates, or even exceeds that of IS6110-RFLP profiling (Supply et al., 1997). In general, the 
discriminatory power of MIRU-VNTR analysis increases with the number of loci evaluated. MIRU-
VNTR typing based on 12 loci is slightly less discriminatory than IS6110-RFLP analysis for M.tb 
isolates with high copy number of IS6110 but at the same time more discriminatory than the IS6110-
RFLP if low copy number IS6110 isolates are investigated (Jagielski et al., 2014). In 2006, a new 
system employing 24 MIRU-VNTR loci was proposed. Of these 24 loci, 15 (including 6 of the 
original set of 12) account for 96% of all detected polymorphisms in M.tb strains, and the 
discriminatory power of this new 24-locus MIRU-VNTR typing system is said to be equal to that 
IS6110-RFLP profiling (Oelemann et al., 2007, Allix-Beguec et al., 2008) 
A particular advantage of the MIRU-VNTR genotyping, compared to the IS6110-RFLP typing, is its 
portability due to digitalization of the generated patterns and therefore simple intra- and inter-
laboratory comparability as well as the amenability to inclusion in web-based databases (Jagielski et 




















CHAPTER 3: METHODOLOGY 
 
3.1  Study design 
3.1.1. Setting  
FOSA TB hospital is a dedicated facility for the treatment of MDR and XDR-TB patients for periods 
ranging from 3 to 18 months. The hospital is a step-down facility (a hospital providing follow-up care 
following initial management in an acute care hospital). It admits patients from King Dini Zulu 
hospital, formerly King George V Hospital, which is the acute care facility for patients with drug 
resistant TB for KZN. The facility has 6 wards (3 male and 3 female wards) with a total of 180 beds 
and a 70-80% bed occupancy rate. At the time of the study, the hospital had a total of 121 MDR-TB 
cases and 43 XDR-TB cases. In some of the wards patients with MDR and XDR-TB were housed 
together due to lack of space. 
3.1.2. Ethical Approval 
This study was approved by the Biomedical Research Ethics Committee at the University of 
KwaZulu-Natal (#BF240/12). Informed consent was obtained from the patients during the recruitment 
process (Annexure 1). 
3.1.3. Specimen Collection 
Following recruitment, baseline sputum specimens were collected from the patients. Two more 
sputum specimens were collected at month 1 and month 2 post-recruitment. The collected sputum 
specimens were transported to the Infection Prevention and Control Department’s TB laboratory at 
the School of Laboratory Medicine, University of KwaZulu-Natal for culture, drug susceptibility 
testing (DST), and genotyping analysis using both IS6110-Restriction Fragment Length 
Polymorphism (RFLP) and spoligotyping. 
3.1.4. Patient Data Collection 
Patient demographic information and data for epidemiological linkages, in the form of questionnaires 
was gathered upon commencement of the study. Additionally, the location of each patient in the ward 
was recorded daily on a ‘bed allocation chart’ (Annexure 2 and 3). Duration of exposure was 
determined retrospectively, as the number of patient days that each individual was in contact with 
other infected patients. Patient contact was categorized as “close contact” if the patient occupied an 
adjacent bed and as “intermediate contact” if the patient was in the same ward. A mobility 
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questionnaire was also administered daily to all patients in an attempt keep track of patients’ 
movements around the ward and their social interactions with other patients.  
Patient clinical outcomes and additional data were obtained via the patient files. The information 
gathered included: age, gender, HIV serology and other blood test results, chest X-rays, patients’ 
previous TB history and current symptoms, DST profile, anti-TB treatment as well as outcomes at the 
end of the study.  
MDR-XDR-TB outcomes were defined as follows (Laserson et al., 2005): 
1. New patient:  a TB treatment naïve patient, or on TB treatment for < 1 month. 
2. Treatment Completed: a patient has completed treatment according to the country’s protocol 
but does not meet the definition of cure or treatment failure due to lack of bacteriological 
results (i.e. fewer than five cultures were performed in the final twelve months of therapy). 
3. Death: a patient who died for any reason during the course of TB treatment. 
4. Transfer out: a patient who has been transferred to another health care unit and for whom the 
treatment outcome is unknown. 
5. Relapse: a patient who has been previously treated for TB and was declared cured or 
treatment completed at the end of the most recent course of treatment, and is now diagnosed 
with a recurrent episode of TB (either a true relapse or a new episode of TB caused by re-
infection). 
6. Treatment failure: a patient who has been previously been treated for TB and whose 
treatment failed at the end of the most recent course of treatment. 
7. Treatment default: a patient whose TB treatment was interrupted for two or more 
consecutive months for any reason. 
8. Loss to follow-up: a patient who has been previously treated for TB and was declared lost to 
follow-up at the end of the most recent course of treatment.  
 
3.2  Specimen Processing 
All specimens were transported to the laboratory within four hours of collection and processed the 
same day as collection. The decontamination procedure involved using the N-acetyl-L-
cysteine/sodium hydroxide (NALC-NaOH) method of (Kent and Kubica, 1985). Direct smear 
microscopy was performed using Ziehl-Neelsen and fluorescent auramine staining for detection of 
acid-fast bacilli (AFB).  
3.2.1. Decontamination of sputum specimens 
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The specimens were processed in the routine TB culture laboratory according to protocol. In brief, 
after digestion and decontamination using the NALC-NaOH method (Kent and Kubica, 1985) 
(Appendix 1.1), the sputum was cultured in MGIT broth, incubated in a Bactec 940 incubator (BD, 
USA) and 7H11 Middlebrook agar plates (Appendix 1.6) (Isenberg, 2004a). 
3.2.2. Culture in Mycobacteria Growth Indicator Tube (MGIT) 
Five hundred micro-litres of decontaminated specimen was added to a MGIT tube containing MGIT 
broth with growth supplement and MGIT PANTA (Polymixin, Amphotericin, Nalidixic acid, 
Trimethorprim, Azlocillin) antibiotic mixture (BD BioSciences, Sparks, MD, USA) (Appendix 1.3). 
The cultures were incubated at 37˚C in a Bactec 940 incubator. H37Rv laboratory strain served as a 
growth control, and a tube containing un-inoculated broth was used as a negative control.  
3.2.3. Culture onto Middlebrook 7H11 agar plates 
One hundred micro-litre of each decontaminated specimen was deposited onto the surface of a 
Middlebrook 7H11 agar plate. A sterile quadloop (Merck, SA) was used to streak the inoculum across 
the entire plate. Plates were incubated in sealed gas permeable bags for 3-6 weeks at 37°C in a regular 
incubator. Plates were viewed weekly for 3 weeks for the presence of M.tb colonies.  
3.2.4. Microscopy 
Ziehl-Neelsen staining was used to confirm the presence of acid-fast bacilli on each of the positive 
MGIT broth. Those containing acid-fast bacilli were then sub-cultured onto Middlebrook 7H11 agar 
plates to obtain single colonies. Plates were heat sealed in gas permeable bags and incubated for 3-6 
weeks at 37°C. Plates were viewed after 3 weeks for the presence of M.tb single colonies, which were 
then inoculated in Middlebrook 7H9 broth (Appendix 1.4) for further growth, followed by inoculation 
onto Lowenstein-Jensen agar slants.  
3.2.5. Culture on Lowenstein-Jensen (LJ) slants 
Each isolate was inoculated into Middlebrook 7H9 broth. Tubes were incubated for 3-6 weeks at 37°C 
until growth was observed. Then the culture was aspirated using a sterile glass pasteur pipette and 
inoculated onto LJ slants. The LJ slants were inverted a few times to spread the inoculum across the 
surface of the slant. The LJ slants were incubated with slightly loosened caps for 3-6 weeks at 37°C. 
These cultures were used to extract DNA for genotyping. 
 
3.3  Identification of culture positive isolates  
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Identification to species level of the growth on Middlebrook 7H11 agar plates was done using two 
biochemical tests, the Nitrate (Appendix 1.7.1) and Niacin (Appendix 1.7.2) tests. If both nitrate and 
niacin tests were positive, this confirmed the culture as being M.tb. 
 
3.4  Drug susceptibility testing (1% Modified Proportion Method) 
The 1% proportion method calculates the proportion of resistant bacilli present in an isolate and is 
considered the “gold standard” method for DST (Kim, 2005). Comparing the number of M.tb colonies 
growing on the drug-free control to that on the drug-containing media, enables the calculation of the 
proportion of drug-resistant colonies for the drug incorporated in the media.   
Colonies from a 3-week old culture were suspended in phosphate buffered saline (PBS) (Merck, SA) 
containing 0.05% Tween-80 (Merck, SA) and 4 sterile glass beads (diameter: 5mm). This suspension 
was thoroughly vortexed following which the remaining clumps were allowed to settle by leaving the 
suspension for 15 minutes undisturbed on the bench. The top layer was aspirated and matched to a 
McFarland standard of 1.0 which is equivalent to + 3.0 × 10
8
 CFU/ml by adding PBS. Four 10-fold 
serial dilutions were done by adding 0.5ml of the suspension of 10
4
 colony forming units per ml 
(cfu/ml) to 4.5 ml PBS. Of this suspension, 100µl was inoculated on quadrants of the Middlebrook 
7H10 agar plates (BD, Difco Laboratories, USA) (Appendix 1.5) containing different drugs (Table 
3.1) and a drug free control. The drug concentrations were chosen according to the WHO 
recommended critical concentrations (WHO, 2007). This resulted in a final inoculum of 10
-3
 
cfu/quadrant. Plates were allowed to dry for 30 minutes and sealed in gas permeable bags and 
incubated at 37°C. Susceptibility tests were read after 3 weeks.  
Table 3.1: Drugs and their respective concentrations used in DST determination 
 
*Obtained from Sigma-Aldrich, USA 
Drug* Concentration 
Isoniazid 1 µg/ml 
Rifampicin 1 µg/ml 
Ethambutol 7.5 µg/ml 
Streptomycin 2 µg/ml 
Ofloxacin 2 µg/ml 
Kanamycin 5 µg/ml 
Ethionamide 5 µg/ml 
Capreomycin 10 µg/ml 
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Any isolate with growth less than 1% in proportion to the drug-free control, was classified as 
susceptible for that drug while growth of 1% or more was classified as resistant (Reichman and 
Hershfield, 2000). 
 
3.5 Genotyping of isolates 
The Cetyltrimethylammonium bromide-Sodium chloride (CTAB-NaCl) method is an isolation 
method most commonly used for attaining high purity mycobacterial DNA (Ramtahal, 2011). M.tb 
colonies were scraped off LJ slants using a sterile swab and suspended into 500µl of sterile distilled 
water. The bacteria were heat killed at 80˚C in a thermomixer comfort (Merck, SA)  for 30 minutes 
following which 70µl of 10% Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA) (Appendix 
2.3.4) solution and 50µl of proteinase K (Roche Diagnostics, Manneheim, Germany) (Appendix 
2.3.3) of concentration 10mg/ml were added to each tube. The tubes were then incubated at 60˚C for 1 
hour. The 5M Sodium chloride (NaCl) (Sigma-Aldrich, USA) (Appendix 2.3.5) and CTAB-NaCl 
(Sigma-Aldrich, USA) (Appendix 2.3.6) solutions were pre-warmed at 60˚C and 100µl of each 
solution was added to each tube and incubated at 60˚C for 15 minutes. 700µl of Chloroform (Sigma-
Aldrich, USA): Isoamyl alcohol (Sigma-Aldrich, USA) (24:1) (Appendix 2.3.7) solution was then 
added to each tube and the tubes were centrifuged for 10 minutes at 12000 rpm. The upper aqueous 
supernatant was transferred to 700µl of Isopropanol (Sigma-Aldrich, USA) and placed in a -20˚C 
freezer for 30 minutes. Following centrifugation for 10 minutes at 12000 rpm, the isopropanol was 
discarded and the pellet was washed with 80% ethanol (Merck, SA) (Appendix 2.3.8) and the pellets 
were left to dry at room temperature for 10 minutes. 55µl of 1xTE buffer (Appendix 2.3.2) was added 
to each pellet and stored at 4˚C overnight or until further use (Van Soolingen et al., 1991) (Appendix 
2.1).  
3.5.1  IS6110-Restriction Fragment Length Polymorphism  
The IS6110-RFLP genotyping technique, using IS6110 as a genetic marker, is recognized as a 
reference standard for strain differentiation of M.tb and is used in epidemiology studies. The 
technique has been widely used for the investigation of outbreaks, the identification of laboratory 
cross-contamination, and distinction between re-infection and relapse (McEvoy et al., 2007).  
Genotyping using IS6110-RFLP was performed as previously described (Van Embden et al., 1993). 
The method includes digestion of genomic DNA with PvuII restriction enzyme which cleaves the 
IS6110 sequence once. It generates DNA fragments that are separated through gel electrophoresis. 
The fragments are then transferred onto a membrane and hybridized with a horseradish peroxidase-
labelled probe complementary to part of the 3’-end of the IS6110 sequence (Jagielski et al., 2014).  
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Extraction and isolation of mycobacterial DNA was performed using the Cetyltrimethylammonium 
bromide-Sodium chloride (CTAB-NaCl) method as previously described (Van Soolingen et al., 1991) 
(Appendix 2.1).  
In order to assess the quality and the concentration of the extracted DNA, gel electrophoresis was 
performed on a 1% agarose gel (Appendix 2.2). Sterile distilled water was used to dilute the DNA to 
the acquired concentration (50µg/ml). Of this DNA 22 µL was mixed with 2.5 µL restriction buffer 
(Roche Diagnostics, Mannheim, Germany) and 1.5 µL of PvuII enzyme (1,000 U (10 U/µl)) (Roche 
Diagnostics, Mannheim, Germany). The restriction reaction mixture was incubated in a water bath at 
37ᵒC for 4 hrs. One microliter of the restricted DNA was run with 5 µL DNA loading buffer on a 1 % 
agarose gel. The gel was initially run at 90 V until the dye front entered the gel then at 36 V overnight 
prior to being visualised under UV. 
The electrophorectically separated fragments were transferred onto a Hybond N
+
 membrane 
(Amersham, Buckinghamshire, UK) by means of vacuum blotting (Appendix 3.2). The membrane 
was air dried for 5 minutes and thereafter placed into the UV cross-linker and exposed by using a 
preset setting of 1200 J. The membrane was removed, rolled and placed into a hybridisation bottle. 
The bottle was then placed in a rotating hybridization oven, set at 42°C, for 24 hours, to ensure 
maximum coverage of the membrane.  
The enhanced chemi- luminescence (ECL) (Amersham, Buckinghamshire, UK) direct system, 
containing a horse-radish peroxidase labelled IS6110 probe was used to detect the presence of a 
nucleotide sequence that is complementary to the probe (target DNA). DNA sequences that have 
moderate to high sequence similarity to the probe were detected by visualization of the hybridized 
probe by autoradiography (Appendix 3.3 & 3.4). 
The GelCompar (Applied Maths, Kortrijk, Belgium) system was used for RFLP fingerprinting 
analysis to determine possible clusters.  
3.5.2  Spoligotyping 
Spoligotyping was performed as previously described (Kamerbeek et al., 1997) and according to the 
procedures described in the Spoligotyping Manual version 4 (2002). 
DNA was isolated using the CTAB-NaCl method (Van Soolingen et al., 1991). Concentration and 
quality of the DNA was checked by means of gel electrophoresis (3.5.1). This was followed by PCR 
of the Direct Repeat (DR) region.  
Genomic DNA isolated from the M.tb cultures was used to amplify the DR region. PCR was done 
prior to hybridisation and PCR products were stored at 4°C until use. The PCR mastermix contained: 
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nuclease free water, colourless GoTaq flexi buffer (Promega, Madison, WI, USA), PCR nucleotide 
mix (Roche Diagnostics, Manneheim, Germany), 20 pmol of each primer DRa (biotinylated) and DRb 
(Whitehead Scientific, IDT, Iowa) and GoTaq DNA Polymerase (Promega, Madison, WI, USA). The 
mastermix was aliquoted into PCR tubes and DNA added to each tube. The tubes were centrifuged 
using a micro-centrifuge (Eppendorf) and placed into the thermocycler (Applied Biosystems) for 
amplification. The following cycling conditions were used: 3 minutes at 96°C, 1 minute at 55°C and 
30 seconds at 72°C for 20 cycles. 
Following fixing the immobilized spacer-oligonucleotides that represented spacers of known 
sequences to the re-usable nylon membrane, the biotin-labelled PCR products were then hybridized to 
the membrane bound probes. After incubation with streptavidin-peroxidase conjugate, ECL detection 
was performed (Appendix 4.1).  
The presence of spacers was detected using ECL as described in 3.5.1 above.  
The patterns were entered in a binary format onto the SITVIT database (Pasteur Institute of 
Guadeloupe: http://www.pasteur-guadeloupe.fr:8081/SITVIT/DEMO), which is an updated version of 
the SpolDB4 database. The corresponding shared international type (SIT) was identified for each 
isolate. The SpolDB4 database was also used to classify isolates into lineages and sub-lineages 
(Brudey et al., 2006). Isolates which had a unique spoligotyping pattern and were not found on the 
international database were classified as ‘orphans’ (Mathuria et al., 2008, Mulenga et al., 2010). 
Dendrograms were constructed using the Bionumerics version 3.5 software (Applied Maths, Kotrijk, 












CHAPTER 4: RESULTS 
4.1 Patients  
The number of patients enrolled in the study was 52. Their main characteristics are summarised in 
Table 4.1.  
Table 4.1: Patient characteristics 
Characteristics  n (%) 
Males 20 (38) 
Females 32 (62) 
  
Total MDR patients on admission   36 (69) 




New patients  24 (46) 
Patients with previous TB history  
 
28 (54) 
HIV-1 infected  





The study population comprised of 20 (38%) males and 32 (62%) females, with an average age of 36 
(range: 19-56 years). In all 52 patients the diagnosis on admission was pulmonary tuberculosis with 
36 (69%) MDR and 16 (31%) XDR-TB cases. With regards to previous TB treatment history, 24 
(46%) patients were classified as new patients (TB treatment naive, or TB treatment for < 1 month), 
and 28 (54%) were patients with a history of previous TB. Forty three (83%) patients were HIV-1 co-
infected while 9 (17%) patients were HIV-1 uninfected. 
Of the 52 patients enrolled, 35 patients had a productive cough and only 12 patients had positive 
cultures at follow-up (Fig.4.1). 
 
4.2 Specimen collection and processing 
An initial sputum for microscopy and culture was collected from 35 patients that had a productive 
cough at baseline collection (Fig. 4.1). Of these, 12 sputum specimens were culture positive at 
baseline. The aim was to collect specimens at three consecutive time points, 1 month apart. However, 















Figure 4.1: Patient flow diagram showing loss of patients at the different sample collection periods.  
Thirteen patients were lost at 1
st
 follow-up due to the inability to produce sputum in 8 patients and 
loss of 5 patients at the planned time of follow-up specimen collection. Twenty-two patients had a 
productive cough at follow-up, but only 12 culture sputum specimens were culture positive. At 2
nd
 
follow-up only two patients agreed to cough, while 3 patients had already been transferred at planned 
time of follow-up. Seventeen patients of the 22, refused to participate in the study. Therefore, a total 
of 59 sputa were cultured of which 28 were positive.   All cultures were identified as M.tb (3.3). 
4.2.1 Drug susceptibility test results 
4.2.1.1   Antimicrobial susceptibility of isolates 
Drug susceptibility profiles were established for all 28 isolates and were compared with the profile in 
the patient’s file as well as between isolates from the same patient at different time points (Table 4.2). 
The consecutive isolates from patients NT1, NT14, NT27 and NT66 showed differences in their 
resistance profiles. The majority of the isolates (89%) were XDR, with the exception of three (11%) 
isolates which were classified as pre-XDR.  
No. of patients 
enrolled at baseline 
52 patients 
No. of patients with no 
productive cough 
17 patients  
No. of patients with 
productive cough 
35 patients  
No. of patients who refused 
participation at 2nd follow-
up 
17 patients  
No. of patients transferred 
before 1st follow-up 
5 patients  
No. of patients with 
productive cough at 1st 
follow-up 
22 patients 
No. of patients transferred 
at 2nd follow-up 
3 patients  
 
No. of patients with no 
productive cough at 1st 
follow-up 
8 patients   
No. of patients with 













                                                                              Study 
      DST results classification                         Result 
   Inh Rif Emb Str Eth Ofl Kan Cap  
NT1* MDR B R R R R R R S S Pre-XDR 
  1
st
 R R R R R R R R XDR 
NT7 MDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT14* MDR B R R S S R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT23 XDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT27* XDR B a R R R R R R R S Pre-XDR 
  B b R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT33 XDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
  2
nd
 R R R R R R R R XDR 
NT36 XDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT41 XDR B R R R R R R R R XDR 
  1
st 
a R R R R R R R R XDR 
  1
st
 b R R R R R R R R XDR 
NT55* MDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
NT66* MDR B R R R R R R S R Pre-XDR 
  1
st
 R R R R R R R R XDR 
  2
nd
 R R R R R R R R XDR 
NT67 MDR B R R R R R R R R XDR 
  1st R R R R R R R R XDR 
NT75 MDR B R R R R R R R R XDR 
  1
st
 R R R R R R R R XDR 
Highlighted in red: Observed DST differences that occurred between sputum collection periods (*)or in 
different isolates from the same sputum (**) -, B: Baseline, 1
st
: first follow-up, 2
nd







Inh: Isoniazid,  Rif: Rifampicin, Emb: Ethambutol, Str: Streptomycin, Ofl: Ofloxacin, Kan: Kanamycin, 
Eth: Ethionamide, Cap: Capreomycin 
 
 
4.3 Genotyping data 
4.3.1 Differentiation of isolates using IS6110 RFLP   
Strain cluster analysis was performed on all the isolates using the GelCompar® system (Applied 
Maths, Kortryk, Belgium). Two or more isolates with fingerprint patterns that do not differ in 2 or 
more bands were defined as a cluster.  
Among the 28 genotyped isolates, 18 (64%) were found to be clustered, or very closely related 
(Figure 4.2). These isolates belonged to the F15/LAM4/KZN family, which is the dominant XDR 
strain found in KZN, SA (Pillay and Sturm, 2007). Nine of the other isolates formed three clusters, 
with each of these clusters displaying a unique fingerprint since these did not have the 
characteristic fingerprint of one of the known families. These clusters were named Unique I, II and 
III. The Unique I cluster consisted of 3 (11%) isolates while Unique II had 4 (14%) isolates and 























































4.4. Genotyping of sequential isolates from individual patients  
 
Figure 4.3: Fingerprint patterns of sequential isolates of individual patients. Panel A: IS6110 RFLP; 



















































































































Panel A Panel B 
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Figure 4.3 compares the genotyping results of isolates from individual patients, and confirms the 
similarity between the IS6110-RFLP results and the spoligotyping results (panel B). The 
differences are summarised in table 4.3.   
Table 4.3: IS6110 genotype results in isolates from consecutive sputum specimens from the same 
patient. 
Patient # Baseline 1
st
 follow up 2
nd
 follow up 
NT01 F15/LAM4/KZN F15/LAM4/KZN N/A 
NT07 F15/LAM4/KZN F15/LAM4/KZN N/A 
NT14 F15/LAM4/KZN Unique II N/A 
NT23 F15/LAM4/KZN F15/LAM4/KZN N/A 
NT27 
F15/LAM4/KZN 
+ Unique II 
F15/LAM4/KZN N/A 
NT33 F15/LAM4/KZN Unique I F15/LAM4/KZN 
NT36 F15/LAM4/KZN Unique I N/A 
NT41 BEIJING 
F15/LAM4/KZN 
+ Unique II 
N/A 
NT55 Unique III Unique III N/A 
NT66 F15/LAM4/KZN F15/LAM4/KZN F15/LAM4/KZN 
NT67 F15/LAM4/KZN Unique I N/A 
NT75 Unique II F15/LAM4/KZN N/A 
 
The sputum of 5 (42%) of the 12 patients (NT 01, 07, 23, 55 and 66) showed the same results at 
the different collection points. Four of the five patients had at each time point isolates that 
belonged to the F15/LAM4/KZN family while the fifth patient showed the Unique III fingerprint 
pattern. Two, of the four patients infected with the F15/LAM4/KZN strain (NT01 and NT23), 
showed the original fingerprint pattern (Pillay and Sturm, 2013), while the other two showed a 
variations on the original banding pattern.  
Seven (58%) of the 12 patients, showed differences in strain fingerprint patterns in sequential 
isolates. Two of these (NT27 and 41) had two different isolates in the same sputum specimen. 
NT27 had two strains in the baseline specimen but only one at follow-up while NT41 had one 
strain in the baseline sputum but two different ones in the follow-up specimen (Fig. 4.4). NT27 
showed a F15/LAM4/KZN fingerprint pattern and a Unique II pattern from the specimen at 
baseline, while NT41 harboured a Beijing isolate in the first specimen but isolates with a 












 time point 
 
4.5. Difference in isolates from patients housed in different hospital wards  
Fingerprint patterns of isolates of patients admitted to the same ward were compared to identify 
possible transmission within the wards.  
 
Figure 4.5: IS6110-RFLP patterns and dendrogram showing clustering strains among female patients 












































































































A total of 16 isolates from 7 female patients were genotyped (Fig. 4.6). Twelve (75%) of the 
isolates were found to have the F15/LAM4/KZN fingerprint pattern. Two (12.5%) belonged to the 
Unique I cluster, and the remaining 2 (12.5%) to the Unique II cluster (Fig 4.5).  
 
Figure 4.6: Comparison of fingerprint patterns of isolates grown at baseline and follow-up amongst 
the female patients within the same ward. 
 
NT01 and NT23 were the only patients whose isolates did not show any differences in fingerprint 
patterns at the different collection points. They both showed the original F15/LAM4/KZN 
fingerprint pattern. 
The other five (71%) patients showed a difference at baseline and follow up. Both isolates from 
patient NT07 belonged to the F15/LAM4/KZN family but differed from each other. The isolate at 
baseline from NT14 also showed a F15/LAM4/KZN fingerprint pattern (with an extra band), and a 
Unique II fingerprint pattern at follow up. NT27 also showed differences in sequential isolates as 
mentioned above (Fig 4.4). NT33 had identical F15/LAM4/KZN fingerprint pattern at baseline and 
2
nd
 follow up. However, the isolate at 1
st
 follow belonged to the Unique II cluster (Fig 4.5). The 
sequence of changing fingerprint patterns in this patient’s isolates suggests mixed infection at least 
from the 1
st
 follow-up date. NT36 showed the F15/LAM4/KZN fingerprint pattern at baseline and 





































































Figure 4.7: IS6110-RFLP patterns and dendrogram showing clustering strains among male patients in 
the same ward. 
 
The genotyping results of 12 isolates from 5 male patients, all admitted to the same ward, are 
shown in Fig 4.7. Eight (67%) of these isolates were found to belong to the F15/LAM4/KZN 
family. Two (18%) sequential isolates from the same patient clustered together depicting the 
Unique III fingerprint pattern (NT55). The isolate of NT67 at 1
st
 follow up showed the Unique I 
fingerprint pattern. The remaining NT 41 baseline isolate had the Beijing fingerprint pattern. 
 
Figure 4.8: Comparison of fingerprint patterns of isolates grown at baseline and follow-up amongst 

















































































































Isolates grown at baseline and follow-up from sputum of patients NT41, NT66, NT67 and NT75 
showed differences in the fingerprint patterns at the different collection points. As previously 
mentioned, NT41 had one isolate with the Beijing fingerprint pattern at baseline and two isolates 
with fingerprints different from the baseline isolate at follow up (Fig 4.4 and Fig 4.8). NT55 
harboured the Unique III strain at the different collection points. NT66 showed identical 
fingerprints, which belonged to the F15/LAM4/KZN family, at baseline and 1
st
 follow up. At 2
nd
 
follow up NT66 showed a fingerprint that was closely related to the F15/LAM4/KZN fingerprint 
with slight variations (Fig 4.7). The NT67 baseline isolate also depicted the F15/LAM4/KZN 
fingerprint, while the 1
st
 follow up isolate showed the Unique I fingerprint (Fig 4.7). Isolates 
retrieved from sputum of patient NT75 at baseline and follow-up differed from each other with a 














CHAPTER 5: DISCUSSION 
General  
The main finding of this study is that of the 12 patients from whom positive follow-up cultures 
were available, 7 harboured according to genotype, a different isolate on follow-up. Most of these 
follow-up specimens were collected 1 month from enrolment. Four of these isolates also differed in 
resistance profile with a more resistant isolate on follow-up. All these patients were on treatment 
for either MDR or XDR TB. One patient’s follow-up isolate was resistant to 2 first-line drugs 
which were obviously not part of the patient’s treatment. The other patients were XDR patients 
with follow-up isolates showing resistance to additional XDR defining drugs. These drugs had not 
been shown effective in these patients or had been replaced by alternatives. Therefore, no 
protection was provided by the current treatment regimens. Risk factors that possibly contributed 
to the acquisition of new strains included HIV infection as well as malnutrition due to prolonged 
TB. 
The follow-up sputum specimens did not contain more than one isolate. One would expect in some 
patients mixed infections with the original and the newly acquired strain. Two different strains 
were found in one of the specimens on enrolment, confirming the technical capability to detect 
this. It is likely that the number of patients was too small for this to be found. 
It cannot be excluded that the follow-up isolates in some of the patients were actually present but 
missed in the specimen collected on enrolment. Cross-contamination during specimen processing 
is unlikely since the dates of processing were different and aseptic procedures were strictly adhered 
to. 
The attempt to identify spacial factors like housed in the same ward or distances between beds 
were not successful due to the mobility of the patients and the high levels of social contact. 
 
5.1. Nosocomial transmission 
We planned to collect sputum specimens at three consecutive time points, 1 month apart from all 
52 patients that were enrolled in the study. This was not achieved due to the inability to produce 
sputum in 17 patients, resulting in 35 sputum specimens being collected at baseline collection (Fig. 
4.1). Thirteen patients were lost at 1
st
 follow-up due to the inability to produce sputum in 8 patients 
and loss of 5 patients at the planned time of follow-up. At 2
nd
 follow-up only two patients agreed to 
continue with the study due to loss of 3 patients who were transferred at the planned time of 
specimen collection and refusal to continue with the study from 17 patients.  This resulted in a total 
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of 59 sputum cultures being collected over the collection periods, of which 28 were culture 
positive by the end of the study. 
Sixty nine percent (69%) and thirty one percent (31%) of the study cohort were initially diagnosed 
with MDR-TB and XDR-TB, respectively. It is worth noting that the initial diagnosis of MDR and 
XDR-TB were gathered from the patient files.  
Drug susceptibility testing is essential for developing effective MDR and XDR-TB treatment 
regimens (Shah et al., 2011). However, with laboratory facilities not being available in most high 
incidence settings, DST is often restricted to high-risk patients (Shah et al., 2011, Mei et al., 2014). 
In 2005, Ghandi, et.al., (2006) reported a large XDR-TB epidemic in Tugela Ferry, South Africa 
(Gandhi et al., 2006) where the XDR-TB isolates from that study, were found to be resistant to all 
6 drugs tested routinely in KZN (Isoniazid, Rifampicin, Ofloxacin, Kanamycin, Ethambutol and 
Streptomycin) (Shah et al., 2011). In 2007, increasing resistance was noted in the same area after 
continuous, routine drug resistance surveillance was implemented for all TB suspects. More than 
90% of the XDR-TB isolates were resistant to all first and second-line drugs routinely tested in 
KZN, SA (Gandhi et al., 2010, Shah et al., 2011).  
In the subsequent Shah, et.al., (2011) study, DST was expanded to include capreomycin and 
ethionamide, which were routinely prescribed for MDR and XDR-TB infected patients. The study 
confirmed that the XDR-TB isolates were resistant to all  first-line and second-line drugs, 
including capreomycin and ethionamide (Shah et al., 2011). These findings resonate with the 
findings from our study as the majority of the culture positive isolates (89%) were found to be 
resistant to all the above mentioned drugs as well (Table 4.2).  Three isolates (11%) showed slight 
changes in their resistance profiles and were found to be pre-XDR.  
Among the 28 genotyped isolates, 18 (72%) were found to belong to one cluster, or were very 
closely related (Fig 4.2). The isolates belonged to the F15/LAM4/KZN family, which is in keeping 
with earlier reports that this strain family is the predominant XDR strain found in KZN, SA. Six 
(24%) of the other isolates also clustered, but did not belong to any of the families dominant in 
KZN.  
In this study, female patients were separated according to resistance profile, in different rooms, 
separating XDR-infected and MDR-infected patients; whereas the male patients, with both MDR 
and XDR-TB, were housed together in the same wards. It is highly likely that this has contributed 
to the transmission of multiple strains of XDR-TB, rather than a single transmission event as 
typically seen in outbreaks (Chihota et al., 2011, Gandhi et al., 2013, Dheda et al., 2014).  
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At the start of the study a TB risk assessment was conducted at the FOSA TB hospital to assess the 
TB-IPC controls in place, the housing facilities and staff knowledge on TB transmission. The 
hospital was found to have an IPC plan in place, including an IPC team and an IPC committee but 
still had several challenges. Firstly, there was no triage system in place for TB patients at FOSA 
TB hospital at the time of the assessment. The problem was found to be that patients who were 
referred from King George V hospital arrived at the FOSA TB hospital as MDR-TB patient and 
the diagnosis of XDR could only be made 8-10 weeks later, contributing to the difficulty of 
implementing a triage system aiming at separating XDR from MDR cases on arrival. Secondly, the 
onsite laboratory facility could only perform microscopic examination of sputum specimens. 
Because there was no radiology facility on site, patients needed to be transported for chest X-ray 
examination, potentially spreading the infection to patients from other hospitals that were also 
referred to that radiology department.  Lastly, MDR-TB and XDR-TB patients were all admitted 
together in the same wards as placement of patients was dependent on bed availability. The 
assessment of the wards revealed that the bed spacing was less than 1 m thus increasing the risk of 
transmission between the patients. Some of the wards had windows that did not allow for cross-
ventilation, and closeness of surrounding buildings prevented the wards from maximizing the use 
of natural ventilation. The above-mentioned challenges could have contributed to drug-resistant 
TB transmission amongst the patients. This is supported by the study of Ghandi et.al., (2013) 
where they concluded that lack of appropriate infrastructure allows for multiple generations of 
drug-resistant strains to be transmitted over time (Gandhi et al., 2013). Furthermore, both female 
and male patients had daily interactions with each other i.e.; doing laundry, braiding each other’s 
hair, or watching television together. The above-mentioned setting also could have contributed to 
drug-resistant TB strain transmission occurring in and outside the wards. 
Basu et al., (2007) and Sissolak et al., (2011) also found that South African hospitals did not have 
the capacity for safe airborne isolation and lacked isolation facilities (Basu et al., 2007, Sissolak et 
al., 2011). Furthermore, Tshitangano et al., (2013) found that IPC interventions in SA were still not 
aligned to the WHO policy on TB infection control in healthcare facilities due to lack of TB 
infection control plans in hospitals (Tshitangano et al., 2013). This greatly contributes to 
nosocomial transmission amongst TB patients in SA (Basu et al., 2007, Sissolak et al., 2011, 
Gandhi et al., 2013).  
The risk of nosocomial transmission is amplified in settings where HIV infection is common 
among patients (Bantubani et al., 2014). 43 (83%) out of the 52 recruited patients in our study 
were found to be HIV-1 co-infected (Table 4.1). All of these were on ARV treatment. Majority of 
the HIV-1 infected patients were smear negative. HIV-infected patients are known to have a low 
bacillary count in their sputa as confirmed by Mendelson (2007). A study conducted at the Church 
of Scotland Hospital (CoSH) in KZN highlighted the possibility of large, highly lethal outbreaks 
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occurring when immuno-suppressed patients in open wards are exposed to other patients with 
unrecognized, or inadequately treated, highly drug resistant strains of M.tb (Bantubani et al., 
2014).  
 
5.2. Mixed strain infections 
The frequent isolation of several different M.tb strain lineages in a single disease episode, often 
with differing drug susceptibilities, has been highlighted by advances made in molecular 
genotyping and recent epidemiological studies (Richardson et al., 2002, Cohen et al., 2011, Cohen 
et al., 2012, Gandhi et al., 2014). These mixed strain infections were previously considered as a 
rare event, but now their occurrence has been shown with increasing frequency (Lazzarini et al., 
2012). This has important implications on drug susceptibility testing and the treatment of patients. 
Genetic heterogeneity of M.tb within a host may arise due to either, i) within-host diversification 
following a single infection event, or ii) re-infection resulting in a mixed infection with more than 
one strain (Garcia de Viedma et al., 2004, Cohen et al., 2011). Mixed strains can differ in their 
resistance and virulence patterns, regardless of the mechanism through which these infections 
occurred (Moodley et al., 2015). Differences in resistance pattern often results from the dominant 
strain surviving the drugs used, thus propagating the most virulent and most resistant strain 
(Lazzarini et al., 2012).  
In this study, molecular genotyping was carried out using IS6110-RFLP, which is recognized as a 
gold standard, and spoligotyping was used as supplementary method for the confirmation of 
IS6110-RFLP results. Strain cluster analysis showed the dominant strain within the cohort to be 
from the F15/LAM4/KZN family.  
The F15/LAM4/KZN strain is a member of the Euro-American strain family, and has been 
dominating among MDR and XDR-TB cases in KZN since 1994 (Pillay and Sturm ,2007) It is 
prominent in this region and has been linked to nosocomial transmission and high mortality rates 
(Gandhi et al., 2006, Pillay and Sturm, 2007, Ioerger et al., 2009, Gandhi et al., 2010, Gandhi et 
al., 2013).  
Only one patient from the cohort was found to be infected with the Beijing strain (NT41). This 
strain was identified at baseline. The Beijing strain has been found in MDR and XDR-TB cases in 
South Africa’s Western Cape and Eastern Cape provinces, but has been commonly found among 
drug-susceptible TB in KZN (Gandhi et al., 2014).  
Moodley, et.al., (2015) showed that 166 (6.3%), out of 2617 patients, displayed discordant 
susceptibility profiles (Moodley et al., 2015). These results were based on phenotypic differences 
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in isolates from different specimens, collected from the same patients on the same day (Moodley et 
al., 2015). The authors argue that the differences found amongst the different specimens collected 
on the same day are a reflection of multiple strain infections as opposed to mutational events 
(Moodley et al., 2015). Even though the DST results from this study showed that majority of the 
patients’ isolates were resistant to all tested antimicrobial drugs, the genotyping results clearly 
show that the patients harboured mixed infections of TB.  
Both female and male patients had daily interactions with each other i.e.; doing laundry, braiding 
each other’s hair, or watching television together. Furthermore, the bed spacing within the wards 
was found to be less than 1 m increasing the chances of transmission between the infected patients. 
The above-mentioned setting could have contributed to the observed nosocomial transmission of 
drug-resistant TB strains. 
This study found a high percentage (67%) of patients to be infected with another strain on follow-
up as compare to the initial one. The observation that most of these follow-up isolates belonged to 
the same cluster indicates that this is likely the result of nosocomial transmission. Other 
explanations for a change in genotype patterns are multiple strain infections where different 
isolates are cultured at different time points as well as laboratory contamination of the specimens 
during the decontamination process. While the first possibility cannot be excluded, it is highly 
unlikely due to the clustering of the follow-up isolates. Laboratory contamination is highly 
unlikely since the culture protocol includes known negative controls with all batches. 
The super-infections took place in patients on treatment for the infection with the initial isolate. 









CHAPTER 6: CONCLUSION 
Nosocomial transmission of tuberculosis is one of the major challenges in the management of the 
TB epidemic in SA and globally. The occurrence of mixed infections in TB patients further 
exacerbates the problem which challenges the infection control strategies in place at healthcare 
facilities. The success of infection control programs depends on the ability to identify and separate 
patients timeously in their respective drug-resistance categories.  This is not always possible when 
resources are scarce and HIV co-infection is prevalent. Implementation of rapid diagnostic testing 
for drug-resistant TB and redesign of healthcare facilities, to minimize congregate spaces, are 
critical elements of infection control programs in addition to administrative, environmental and 
personal protective measures.  
The findings in this study are subject to a few limitations. Firstly, our findings are likely a minimal 
estimate of nosocomial transmission, since the majority of the patient cohort was lost to follow-up 
(Fig. 4.1), and some isolates were lost due to contamination. It is likely that we would have found 
more epidemiologic links and additional XDR-TB transmission among already infected patients. 
Secondly, our genotyping data was also incomplete because of the loss of some isolates to 
contamination; therefore the size of the clusters is likely an underestimate which could have 
resulted in unidentified links in the transmission network. A larger, more comprehensive 
investigation as well stringent follow up measures over a prolonged period would give better 




















1. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-
TB): 2010 global report on surveillance and response. Geneva. 
2. World Health Organization. 2014. Global Tuberculosis Report 2014. World Health 
Organization Document WHO/HTM/TB/2014.08. 1-171 (2014). 
3. World Health Organization. WHO-IUTALD Global Project on Anti-Tuberculosis Drug 
Resistance Surveillance. (2008). Anti-Tuberculosis Drug Resistance in the World (Report 
No.4) [Online]. Available: 
http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf [Accessed 09 October 
2014]. 
4. ALEXANDER, P. E. & DE, P. 2007. The emergence of extensively drug-resistant 
tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resukting public 
health threat from extensively drug-resistant TB, globally and in Canada. Canadian 
Journal of Infectious Diseases and Medical Microbiology, 18, 289-291. 
5. ALLAND, D., KALKUT, G. E., MOSS, A. R., MCADAM, R., HAHN, J. A., 
BOSWORTH, W., DRUCKER, E. & BLOOM, B. R. 1994. Transmission of tuberculosis 
in New York City. An analysis by DNA fingerprinting and conventional epidemiologic 
methods. The New England Journal of Medicine, 330, 1710-1716. 
6. ALLIX-BEGUEC, C., HARMENS, D., WENIGER, T., SUPPLY, P. & NIEMANN, S. 
2008. Evaluation and strategy for use of of MIRU-VNTRplus, a multifunctional database 
for online analysis of genotyping data and phylogenetic identification of Mycobacterium 
tuberculosis complex isolates. Journal of Clinical Microbiology, 46, 2692-2699. 
7. ANDREWS, J., NOUBARY, F., WALENSKY, R. P., CERDA, R., LOSINA, E. & 
HORSBURGH, C. R. 2012. Risk of progression to active tuberculosis following 
reinfection with Mycobacterium tuberculosis. Clinical Infectious Diseases, 54, 784-791. 
8. BANTUBANI, N., KABERA, G., CONNOLLY, C., RUSTOMJEE, R., REDDY, T., 
COHEN, T. & PYM, A. S. 2014. High rates of potentially infectious tuberculosis and 
multdrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu-Natal, 
South Africa indicate risk of nosocomial transmission. PLOS ONE, 9, 1-7. 
9. BASU, S., ANDREWS, J. R., POOLMAN, E. M., GANDHI, N. R., SHAH, N. S., MOLL, 
A., MOODLEY, P., GALVANI, A. P. & FRIEDLAND, G. H. 2007. Prevention of 
Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in Rural South 
African District Hospitals: An Epidemiological Modelling Study. Lancet, 370, 1500-1507. 
10. BATES, J. H. & NARDELL, E. A. 1995. Institutional Control Measures for Tuberculosis 
in the Era of Multiple Drug Resistance. . ACCP/ATS Consensus Conference. Chest. 
41 
 
11. BEYERS, N., GIE, R. P., ZIETSMAN, H. L., KUNNEKE, M., HAUMANN, J., 
TATLEY, M. & DONALD, P. R. 1996. The use of a geographical information system 
(GIS) to evaluate the distribution of tuberculosis in a high-incidence community. . South 
African Medical Journal, 86, 40-44. 
12. BROWN, T., NIKOLAYEVSKY, V., VELJI, P. & DROBNIEWSKI, F. 2010. 
Associations between Mycobacterium tuberculosis strains and phenotypes. Emerging 
Infectious Diseases, 16, 272-280. 
13. BRUDEY, K., DRISCOLL, J. R., RIGOUTS, L., PRODINGER, W. M., GORI, A., AL-
HAJOJ, S. A., ARISTIMUNO, L., ARORA, J., BAUMANIS, V., BINDER, L., 
CARFRUNE, P., CATALDI, A., CHEONG, S., DIEL, R., ELLERMEIER, C., EVANS, J. 
T., FAUVILLE-DUFAUX, M., FERDINAND, S., GARCIA DE VIEDMA, D., 
GARZELLI, C., GAZZOLA, L., GOMES, H. M., GUITTIEREZ, M. C., HAWKEY, P. 
M., VAN HELDEN, P., KADIVAL, G. V., KREISWIRTH, B. N., KREMER, K., KUBIN, 
M., KULKARNI, S. P., LIENS, B., LILLEBAEK, T., HO, M. L., MARTIN, C., 
MORROUSOV, I., MARTIN, C., NARVSKAIA, O., NGEOW, Y. F., NAUMANN, L., 
NIEMANN, S., PARWATI, I., RAHIM, Z., RASOLOFO-RAZANAMPARANY, V., 
RASOLONAVALONA, T., ROSSETTI, M. L., RUSCH-GERDES, S., SAJDUDA, A., 
SAMPER, S., SHEMYAKIN, I. G., SINGH, U. B., SOMOSKOVI, A., SKUCE, R. A., 
VAN SOOLINGEN, D., STREICHER, M. E., SUFFYS, P. N., TORTOLI, E., 
TRAVEVSKA, T., VINCENT, V., VICTOR, T., WARREN, R., YAP, S. F., ZAMAN, K., 
PORTAELS, F., RASTOGI, N. & SOLA, C. 2006. Mycobacterium tuberculosis complex 
genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for 
classification, population genetics and epidemiology. BMC Microbiology, 6, 1-17. 
14. CANETTI, G., SUTHERLAND, I. & SVANDOVA, E. 1972. Endogenous reactivation 
and exogenous reinfection: their relative importance with regard to the development of 
non-primary tuberculosis. Bulletin of the International Union against Tuberculosis and 
Lung Disease, 66, 211-213. 
15. CHAKRABORTY, N., DE, C., BHATTACHARYYA, S., MUKHERJEE, A., SANTRA, 
S., BANERJEE, D., SARKAR, R. & GUHA, S. 2010. Drug susceptibility profile of 
Mycobacterium tuberculosis isolated from HIV infected and uninfected pulmonary 
tuberculosis patients in Eastern India. Transaction of the Royal Society of Tropical 
Medicine and Hygiene, 104, 195-201. 
16. CHIANG, C. & RILEY, W. 2005. Exogeous reinfection in tuberculosis. Lancet Infectious 
Diseases, 5, 629-636. 
17. COHEN, K. A., ABEEL, T., MCGUIRE, A. M., DESJARDINS, C. A., MUNSAMY, V., 
SHEA, T. P., WALKER, B. J., BANTUBANI, N., ALMEIDA, D. V., ALVARADO, L., 
CHAPMAN, S., MVELASE, N. R., DUFFY, E. Y., FITZGERALD, M., GOVENDER, P., 
42 
 
GUJJA, S., HAMILTON, S., HOWARTH, C., LARIMER, J. D., MAHARAJ, K., 
PEARSON, M. D., PRIEST, M. E., ZENG, Q., PADAYATCHI, N., GROSSET, J., 
YOUNG, S. K., WORTMAN, J., MLISANA, K. P., O'DONNELL, M. R., BIRREN, B. 
W., BISHAI, W. R., PYM, A. S. & EARL, A. M. 2015. Evolution of extensively drug-
resistant tuberculosis over four decades revealed by whole genome sequencing of 
Mycobacterium tuberculosis from KwaZulu-Natal South Africa. International Journal of 
Mycobacteriology, 4, 24-25. 
18. COHEN, T., MURRAY, M., WALLENGREN, K., ALVAREZ, G. G., SAMUEL, E. Y. & 
WILSON, D. 2010. The prevalence and drug sensitivity of tuberculosis among patients 
dying in hospital in KwaZulu-Natal, South Africa: A postmortem study. PlOS Medicine, 7, 
1-8. 
19. COHEN, T., VAN HELDEN, P., WILSON, D., COLIJN, C., MCLAUGHLIN, M. M., 
ABUBAKAR, I. & WARREN, R. 2012. Mixed-strain Mycobacterium tuberculosis 
infections and the implications for tuberculosis treatment and control. Clinical 
Microbiology Reviews, 25, 708-719. 
20. COHEN, T., WILSON, D., WALLENGREN, K., SAMUEL, E. Y. & MURRAY, M. 
2011. Mixed-Strain Mycobacterium tuberculosis Infections among Patients Dying in a 
Hospital in KwaZulu-Natal, South Africa. Journal of Clinical Microbiology, 49, 385-388. 
21. COHN, D. L. & O'BRIEN, R. J. 1998. The Use of Restriction Fragment Length 
Polymorphism (RFLP) Analysis for Epidemiological Studies of Tuberculosis in 
Developing Countries. International Journal of Tuberculosis and Lung Disease, 2, 16-26. 
22. COMAS, I., HOMOLKA, S., NIEMANN, S. & GAGNEUX, S. 2009. Genotyping of 
genetically monomorphic bacteria: DNA sequencing in Mycobacterium tuberculosis 
highlights the limitations of current methodologies. PLOS ONE, 4, 1-11. 
23. COOKE, G. S., BEATON, R. K., ASHWORTH, S., JOHN, L., KON, O. M., WILLIAMS, 
O. M., PYM, A. S. & MOODLEY, P. 2011. International spread of MDR-TB from Tugela 
Ferry, South Africa. Emerging Infectious Diseases, 17, 2035-2037. 
24. CORBETT, E. L., WATT, C. J., WALKER, N., MAHER, D., WILLIAMS, B. G., 
RAVIGLIONE, M. C. & DYE, C. 2003. The growing burden of tuberculosis: global trends 
and interactions with the HIV epidemic. Archives of Internal Medicine 163, 1009-1021. 
25. COX, H. S., MCDERMID, C., AZEVEDO, V., MULLER, O., COETZEE, D., SIMPSON, 
J., BARNARD, M., COETZEE, G., VAN CUTSEM, G. & GOEMAERE, E. 2010. 
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV 
prevalence setting in Khayelitsha, South Africa. PLOS ONE, 5, 1-8. 
26. DALEY, C. L., SMALL, P. M., SCHECTER, G. F., SCHOOLNIK, G. K., MCADAM, R. 
A., JACOBS, W. R. & HOPEWELL, P. C. 1992. An Outbreak of Tuberculosis with 
Accelerated Progression Among Persons Infected with the Human Immunodeficiency 
43 
 
Virus: An Analysis using Restriction Fragment-Length Polymorphism. The New England 
Journal of Medicine, 326, 231-235. 
27. DANIEL, T. M. 2006. The history of tuberculosis. Respiratory Medicine., 100, 1862-1870. 
28. DOOLEY, S. W., VILLARINO, M. E., LAWRENCE, M., SALINAS, L., AMIL, S., 
RULLAN, J. V., JARVIS, W. R., BLOCH, A. B. & CAUTHEN, G. M. 1992. Nosocomial 
Transmission of Tuberculosis in a Hospital Unit for HIV-Infected Patients. The Journal of 
American Medical Association, 267. 
29. DUCATI, R. G., RUFFINO-NETTO, A., BASSO, L. A. & SANTOS, D. S. 2006. The 
resumption of consumption - a review on tuberculosis, Memorias Instituto Oswaldo Cruz. 
30. ESCOMBE, A. R., HUAROTO, L., TICONA, E., BURGOS, M., SANCHEZ, I., 
CARRASCO, L., FARFAN, E., FLORES, F. & MOORE, D. A. 2010. Tuberculosis 
transmission risk and infection control in hospital emergency department in Lima, Peru. 
International Journal of Tuberculosis and Lung Disease, 14, 1120-112. 
31. FRIEDEN, T. R., STERLING, T. R., MUNSIFF, S. S., WATT, C. J. & DYE, C. 2003. 
Tuberculosis. Lancet, 362, 887-899. 
32. GANDHI, N., ANDREWS, J., BRUST, J. C. M., MONTREUIL, R., WEISSMAN, D., 
HEO, M., MOLL, A., FRIEDLAND, G. & SHAH, N. S. 2012. Risk factors for mortality 
among MDR- and XDR-TB patients in a high HIV-prevalence setting. International 
Journal of Tuberculosis and Lung Disease, 16, 90-97. 
33. GANDHI, N., BRUST, J. C. M., MOODLEY, P., WEISSMAN, D., HEO, M., NING, Y., 
MOLL, A., FRIEDLAND, G., STURM, A. W. & SHAH, N. S. 2014. Minimal diversity of 
drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerging Infectious 
Diseases, 20, 426-433. 
34. GANDHI, N., MOLL, A., STURM, A., PAWINSKI, R., GOVENDER, T., LALLOO, U., 
ZELLER, K., ANDREWS, J. & FRIEDLAND, G. 2006. Extensively drug-resistant 
tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural 
area of South Africa. Lancet, 368, 1575-1580. 
35. GANDHI, N., SHAH, N. S., ANDREWS, J., VELLA, V., MOLL, A., SCOTT, M., 
WEISSMAN, D., MARRA, C., LALLOO, U., FRIEDLAND, G. & COLLABORATION, 
T. F. C. A. R. T. C. 2010. HIV coinfection in multidrug- and extensively drug-resistant 
tuberculosis results in high early mortality. American Journal of Respiratory and Critical 
Care Medicine, 181, 80-86. 
36. GANDHI, N., WEISSMAN, D., MOODLEY, P., RAMTAHAL, M., ELSON, I., 
KREISWIRTH, B., MATHEMA, B., SHASHKINA, E., ROTHENBERG, R., MOLL, A., 
FRIEDLAND, G., STURM, A. & SHAH, N. 2013. Nosocomial transmission of 
extensively drug-resistant tuberculosis in a rural hospital in South Africa. Journal of 
Infectious Diseases, 1-9. 
44 
 
37. GORI, A., BANDERA, A., MARCHETTI, G., DEGLI ESPOSTI, A., CATOZZI, L., 
NARDI, G. P., GAZZOLA, L., FERRARIO, G., VAN EMBDEN, J. D. A., VAN 
SOOLINGEN, D., MORONI, M. & FRANZETTI, F. 2005. Spoligotyping and 
Mycobacterium tuberculosis. Emerging Infectious Diseases, 11. 
38. GROBUSCH, M. P. 2010. Drug-resistant and extensively drug-resistant tuberculosis in 
southern Africa. Current Opinion in Pulmonary Medicine, 16, 180-185. 
39. HAEILI, M., DARBAN-SAROKHALIL, D., FOOLADI, A. A. I., JAVADPOUR, S., 
HASHEMI, A., SIAVOSHI, F. & FEIZABADI, M. M. 2013. Spoligotyping and drug 
resistance patterns of Mycobacterium tuberculosis isolates from five provinces of Iran. 
MicrobiologyOpen, 2, 988-996. 
40. HANEKOM, M., STRECHER, E., VAN DER BERG, D., COX, H. S., MCDERMID, C., 
BOSMAN, M., GEY VAN PITTIUS, N. C., VICTOR, T., KIDD, M., VAN 
SOOLINGEN, D., VAN HELDEN, P. & WARREN, R. 2013. Population structure of 
mixed Mycobacterium tuberculosis infection is strain genotype and culture medium 
dependent. PLOS ONE, 8, 1-6. 
41. HERMANS, P., VAN SOOLINGEN, D., DALE, J. W., SCHUITEMA, A. R., MCADAM, 
R., CATTY, D. & VAN EMBDEN, J. D. A. 1990. Insertion element IS986 from 
Mycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis. 
Journal of Clinical Microbiology, 28, 2051-2058. 
42. ISENBERG, H. D. 2004a. Clinical Microbiology Procedures Handbook: Conventional 
Biochemicals, Washington D C, American Society for Microbiology. 
43. JAGIELSKI, T., VAN INGEN, J., RASTOGI, N., DZIADEK, J., MAZUR, P. K. & 
BIELECKI, J. 2014. Current Methods in the Molecular Typing of Mycobacterium 
tuberculosis and Other Mycobacteria. BioMed Research International, Hindawi, 1-21. 
44. JARVIS, W. R. 1995. Nosocomial transmission of multidrug-resistant Mycobacterium 
tuberculosis. American Journal of Infection Control, 23, 146-151. 
45. JAWAHAR, M. S. 2004. Current trends in chemotherapy of tuberculosis. Indian Journal 
of Medical Research, 120, 398-417. 
46. KAMERBEEK, J., SCHOULS, L. M., KOLK, A., VAN AGTERVELD, M., VAN 
SOOLINGEN, D., KUIJPER, S., BUNSCHOTEN, A., MOLHUIZEN, H., SHAW, R., 
GOYAL, M. & VAN EMBDEN, J. D. A. 1997. Simultaneous detection and strain 
differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. Journal of 
Clinical Microbiology, 35, 907-914. 
47. KARIM, S. S. A., CHURCHYARD, G., KARIM, Q. & LAWN, S. 2009. HIV Infection 
and tuberculosis in South Africa: An urgent need to escalate the public health response. 
Lancet, 374, 921-933. 
45 
 
48. KASPROWICZ, V. O., ACHKAR, J. M. & WILSON, D. 2011. The tuberculosis and HIV 
epidemic in South Africa and the KwaZulu-Natal Research Institute  for Tuberculosis and 
HIV. Journal of Infectious Diseases, 204. 
49. KATO-MAEDA, M., METCALFE, J. Z. & FLORES, L. 2011. Genotyping of 
Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiology, 
6, 203-216. 
50. KAUFMANN, S. H. & SCHAIBLE, U. E. 2005. 100th anniversary of Robert Koch's 
Nobel Prize for the discovery of the tubercle bacillus. Trends Microbiology, 13, 469-475. 
51. KELLEND, K. 2014. South Africa risks spreading totally drug-resistant TB-study. 
Available: http://www.reuters.com/article/2014/01/17/us-tuberculosis-southafrica-
idUSBREA0G00B20140117 [Accessed 06 October 2014]. 
52. KENT, P. T. & KUBICA, G. P. 1985. Pubic health mycobacteriology. A guide for the 
level III laboratory. , Atlanta, GA, Centers for Disease Control and Prevention. 
53. KIM, S. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results 
European Respiratory Journal, 25. 
54. KLOPPER, M., WARREN, R., HAYES, C., VAN PITTIUS, N. C. G., STREICHER, M. 
E., MULLER, B., SIRGEL, F. A., CHABULA-NXIWENI, M., HOOSAIN, E., 
COETZEE, G., VAN HELDEN, P., VICTOR, T. & TROLLIP, A. P. 2013. Emergence 
and Spread of Extensively and Totally Drug-Resistant Tuberculosis, South Africa. 
Emerging Infectious Diseases, 19, 449-455. 
55. KREMER, K., VAN SOOLINGEN, D., FROTHINGHAM, R., HAAS, W. H., 
HERMANS, P., MARTIN, C., PALITTAPONGARNPIM, P., PLIKAYTIS, B. B., 
RILEY, W., YAKRUS, M. A., MUSSER, J. M. & VAN EMBDEN, J. D. A. 1999. 
Comparison of Methods Based on Different Molecular Epidemiological Markers for 
Typing of Mycobacterium tuberculosis Complex Strains: Interlaboratory Study of 
Discriminatory Power and Reproducibility. Journal of Clinical Microbiology, 37, 2607-
2618. 
56. LASERSON, K. F., THORPE, L. E., LEIMANE, V., WEYER, K., MITNICK, C. D., 
RIEKSTINA, V., ZAROVSKA, E., RICH, M. L., FRASER, H. S., ALARCON, E., 
CEGIELSKI, J. P., GRZEMSKA, M., GUPTA, R. & ESPINAL, M. 2005. Speaking the 
same language: treatment outcome definitions for multidrug-resistant tuberculosis. 
International Journal of Tuberculosis and Lung Disease, 9, 640-645. 
57. LOERGER, T. R., KOO, S., NO, E., CHEN, X., LARSEN, M. H., JACOBS, W. R., 
PILLAY, M., STURM, A. W. & SACCHETTINI, J. C. 2009. Genome analysis of multi- 




58. MAGANA-ARACHCHI, D. M. 2013. Epidemiology of Multidrug-Resistant Tuberculosis 
(MDR-TB) (Chapter 11) Intech, 183-201. 
59. MARAHATTA, S. B. 2010. Multi-drug resistant tuberculosis burden and risk factors: an 
update. Kathmandu University Medical Journal, 29, 116-125. 
60. MATHURIA, J. P., SHARMA, P., PRAKASH, P., SAMARIA, J. K., KATOCH, V. M. & 
ANUPURBA, S. 2008. Role of spoligotyping and IS6110-RFLP in assessing genetic 
diversity of Mycobacterium tuberculosis in India. Infection, Genetics and Evolution, 8, 
346-351. 
61. MBABAZI, D. & OUIFKI, R. 2010. Can mixed infection explain the high prevalence of 
TB in crowded areas with high strain diversity and low HIV prevalence? SACEMA, 1-3. 
62. MCEVOY, C., FALMER, A. A., GEY VAN PITTIUS, N. C., VICTOR, T., VAN 
HELDEN, P. & WARREN, R. 2007. The role of IS6110 in the evolution of 
Mycobacterium tuberculosis. Tuberculosis, 87, 393-404. 
63. MCGOWAN, J. E. 1995. Nosocomial tuberculosis: New progress in control and 
prevention. Clinical Infectious Diseases, 21, 489-505. 
64. MENZIES, D., FANNING, A. & FITZGERALD, M. 1995. Tuberculosis among health 
care workers. The New England Journal of Medicine, 332, 92-98. 
65. MILLER, A. C., SHARNAPRAPAI, S., SURUKI, R., CORKREN, E., NARDELL, E. A., 
DRISCOLL, J. R., TABER, H. & ETKIND, S. 2002. Imapct of Genotyping of 
Mycobacterium tuberculosis on Public Health Practice in Massachusetts. Emerging 
Infectious Diseases, 8, 1285-1289. 
66. MITCHISON, D. A. 2005. The control of tuberculosis: progress and prospect. The Indian 
Journal of Medical Research, 121, 137-139. 
67. MLAMBO, C. 2011. Molecular and epidemiological characterization of multidrug-
resistant Mycobacterium tuberculosis isolates in Johannesburg, South Africa. Doctor of 
Philosophy, University of the Witwatersrand, Johannesburg. 
68. MLAMBO, C., WARREN, R., POSWA, X., VICTOR, T., DUSE, A. & MARAIS, E. 
2008. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South 
Africa. The International Journal of Tuberculosis and Lung Disease, 12, 99-104. 
69. MRC 1950. Treatment of pulmonary tuberculosis with streptomycin and para-
aminosalicyclic acid. BMJ, 2, 1073-1085. 
70. MULENGA, C., SHAMPUTA, I. C., MWAKAZANGA, D., KAPATA, N., PORTAELS, 
F. & RIGOUTS, L. 2010. Diversity of Mycobacterium tuberculosis genotypes circulating 
in Ndola, Zambia. BMC Infectious Diseases, 10, 177. 
71. NARDELL, E. A. 2004. Catching droplet nuclei: Toward a better understanding of 




72. NARITA, M., KELLMAN, M., FRANCHINI, D. L., MCMILLAN, M. E., HOLLENDER, 
E. S. & ASHKIN, D. 2002. Short-course rifampycin and pyrazinamide treatment for latent 
tuberculosis infection in patients with HIV infection: the 2-year experience of a 
comprehensive community-based program in Broward County, Florida. Chest, 122, 1292-
1298. 
73. O'SULLIVAN, M. V. N., ZHOU, F., SINTCHENKO, V., KONG, F. & GILBERT 2011. 
Multiplex PCR and Reverse Line Blot Hybridization Assay (mPCR/RLB). Journal of 
Visualized Experiments: Centre for Infectious Diseases and Microbiology, University of 
Sydney. 
74. OELEMANN, M. C., DIEL, R., VATIN, V., HAAS, W. H., RUSCH-GERDES, S., 
LOCHT, C., NIEMANN, S. & SUPPLY, P. 2007. Assessment of an optimized 
mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing system 
combined with spoligotyping for population-based molecular epidemiology studies of 
tuberculosis. Journal of Clinical Microbiology, 45, 691-697. 
75. PARSONS, S., ABBOTT, G., DE JAGER, P., CONRADIE, D. & BOLE, S. 2010. 
Researched solutions for long-term accomodation units for drug-resistant tuberculosis 
patients in South Africa. Science real and relevant conference. 
76. PEARSON, M. L., JEREB, J. A., FRIEDEN, T. R., CRAWFORD, J. T., DAVIS, B. J., 
DOOLEY, S. W. & JARVIS, W. R. 1992. Nosocomial Transmission of Multidrug-
resistant Mycobacterium tuberculosis: A Risk to Patients and Health Care Workers. Annals 
of Internal Medicine, 117, 191-196. 
77. PILLAY, M. & STURM, A. W. 2010. Nosocomial transmission of the F15/LAM4/KZN 
genotype of Mycobacterium tuberculosis in patients on tuberculosis treatment. 
International Journal of Tuberculosis and Lung Disease, 14, 223-230. 
78. RAMTAHAL, M. A. 2011. Spread of Multidrug-Resistant Tuberculosis (MDR-TB), 
including Extensively Drug Resistant Tuberculosis (XDR-TB), in rural KwaZulu-Natal. 
Masters in Medical Science, Nelson R Mandela School of Medicine. 
79. RAVIGLIONE, M. C., SUDRE, P., RIEDER, H. L., SPUNACI, S. & KOCHI, A. 1993. 
Secular trends of tuberculosis in Western Europe. Bull World Health Organ, 71, 297-306. 
80. REED, M. B., DOMENECH, P., MANCA, C., SU, H., BARCZAK, A. K., 
KREISWIRTH, B. N., KAPLAN, G. & BARRY, C. E. 2004. A glycolipid of 
hypervirulent tuberculosis strains that inhibits the innate immune response. Nature, 431, 
84-87. 
81. REICHMAN, L. B. & HERSHFIELD, E. S. 2000. Tuberculosis: A Comprehensive 
International Approach., New York, Marcel Dekker. 
82. RICHARDSON, M., CAROLL, N. M., ENGELKE, E., VAN DER SPUY, G., SALKER, 
F., MUNCH, Z., GIE, R. P., WARREN, R., BEYERS, N. & VAN HELDEN, P. 2002. 
48 
 
Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-
incidence community setting. Journal of Clinical Microbiology, 40, 2750-2754. 
83. SELEKMAN, J. 2006. Changes in the Screening for Tuberculosis in Children. Pediatric 
Nursing [Online], 32.  [Accessed 25 July 2014]. 
84. SHAMPUTA, I. C., JUGHELI, L., SADRADZE, N., WILLERY, E., PORTAELS, F., 
SUPPLY, P. & RIGOUTS, L. 2006. Mixed infection and clonal representativeness of a 
single sputum sample in tuberculosis patients from a penetentiary hospital in Georgia. 
Respiratory Research, 7, 1-10. 
85. SHENOI, S., BROOKS, R., BARBOUR, R., ALTICE, F., ZELTERMAN, D., MOLL, A., 
MASTER, I., VAN DER MERWE, T. & FRIEDLAND, G. 2012. Survival from XDR-TB 
is associated with modifiable clinical characteristics in rural South Africa. PLOS ONE, 7, 
1-8. 
86. SHENOI, S., HEYSELL, S., MOLL, A. & FRIEDLAND, G. 2009. Multidrug-resistant 
and extensively drug-resistant tuberculosis: consequences for the global HIV community. 
Current Opinion in Infectious Diseases, 22, 11-17. 
87. SISSOLAK, D., MARAIS, F. & MEHTAR, S. 2011. TB infection prevention and control 
experiences of South African nurses - a phenomenological study. BMC Public Health, 11, 
1-10. 
88. SMALL, P. M., SHAFER, R. W., HOPEWELL, P. C., SINGH, S. P., MURPHY, M. J., 
DESMOND, E., SIERRA, M. F. & SCHOOLNIK, G. K. 1993. Exogenous Reinfection 
with Multidrug-Resistant Mycobacterium tuberculosis in Patients with Advanced HIV 
Infection. New England Journal of Medicine, 328, 1137-1144. 
89. SOUGAKOFF, W. 2011. Molecular epidemiology of multidrug-resistant strains of 
Mycobacterium tuberculosis. Clinical Microbiology and Infection, 17, 800-805. 
90. SUPPLY, P., MAGDALENA, J., HIMPSENS, S. & LOCHT, C. 1997. Identification of 
novel intergenic repetitive units in a mycobacterial two-component system operon. 
Molecular Microbiology, 26, 991-1003. 
91. SUPPLY, P., MAZARS, E., LESJEAN, S., VINCENT, V., GICQUEL, B. & LOCHT, C. 
2000. variable human minisatellite-like regions in the Mycobacterium tuberculosis 
genome. Molecular Microbiology, 36, 762-771. 
92. TANG, J. W., LI, Y., EAMES, I., CHAN, P. K. & RIDGWAY, G. L. 2006. Factors 
involved in the aerosol transmission of infection and control of ventilation in healthcare 
premises. The Journal of Hospital Infection, 64, 100-114. 
93. TSHITANGANO, T. G., MAPUTLE, T. S. & NETSHIKWETA, M. L. 2013. 
Environmental tuberculosis control measures at resource-limited hospitals in Vhembe 
district, Limpopo Province, South Africa. African Journal for Physical, Health Education, 
Recreation and Dance, 19, 107-115. 
49 
 
94. ULRICH, R., ZIMRING, C., ZHU, X., DUBOSE, J., SEO, H., CHOI, Y., QUAN, X. & 
JOSEPH, A. 2008. Review of the research literature on evidence-based healthcare design. 
Health Environments Research and Design (HERD), 1. 
95. ULRICHS, T. & KAUFMANN, S. H. 2002. Mycobacterial Persistence and Immunity. 
Frontiers in Bioscience, 458-469. 
96. VAN EMBDEN, J. D. A., CAVE, M. D., CRAWFORD, J. T., DALE, J. W., EISENACH, 
K. D., GICQUE, L. B., HERMANS, P., MARTIN, C., MCADAM, R., SHINNICK, T. M. 
& SMALL, P. M. 1993. Strain Identification of Mycobacterium tuberculosis by DNA 
Fingerprinting: Recommendations for a Standardized Methodology. Journal of Clinical 
Microbiology, 31, 406-409. 
97. VAN EMBDEN, J. D. A., VAN GORKOM, T., KREMER, K., JANSEN, R., VAN DER 
ZEIJST, B. A. & SCHOULS, L. M. 2000. Genetic variation and evolutionary origin of the 
direct repeat locus of Mycobacterium tuberculosis complex bacteria. Journal of 
Bacteriology, 182, 2393-2401. 
98. VAN RIE, A., VICTOR, T., RICHARDSON, M., JOHNSON, R., VAN DER SPUY, G., 
MURRAY, E. J., BEYERS, N., GEY VAN PITTIUS, N. C., VAN HELDEN, P. & 
WARREN, R. 2005a. Reinfection and mixed infection cause changing Mycobacterium 
tuberculosis drug-resistance patterns. American Journal of Respiratory and Critical Care 
Medicine, 172, 636-642. 
99. VAN RIE, A., WARREN, R., RICHARDSON, M., VICTOR, T., GIE, R. P., ENARSON, 
D. A., BEYERS, N. & VAN HELDEN, P. 1999. Exogenous reinfection as a cause of 
recurrent tuberculosis after curative treatment. New England Journal of Medicine, 341, 
1174-1179. 
100. VAN RIE, A., WARREN, R., RICHARDSON, M., VICTOR, T., JOHNSON, R., 
VAN DER SPUY, G., MURRAY, E. J., BEYERS, N., GEY VAN PITTIUS, N. C. & 
VAN HELDEN, P. 2005b. Reinfection and mixed infection cause changing 
Mycobacterium tuberculosis drug-resistance patterns. American Journal of Respiratory 
and Critical Care Medicine, 172, 636-642. 
101. VAN SOOLINGEN, D., HERMANS, P. W. M., DE HAAS, P. E. W., SOLL, D. 
R. & VAN EMBDEN, J. D. A. 1991. The occurrence and stability of insertion sequences 
in Mycobacterium tuberculosis complex strains; evaluation of IS-dependent DNA 
polymorphism as a tool in the epidemiology of tuberculosis Journal of Clinical 
Microbiology, 29, 2578-2586. 
102. WADA, M. 2007. Anti-tuberculosis chemotherapy. Kekkaku, 82, 771-781. 
103. WARREN, R., VICTOR, T., VICTOR, E. M., STREICHER, M. E., 
RICHARDSON, M., BEYERS, N., GEY VAN PITTIUS, N. C. & VAN HELDEN, P. 
50 
 
2004. Patients with active tuberculosis often have different strains in the same sputum 
specimen. American Journal of Respiratory and Critical Care Medicine, 169, 610-614. 
104. WHITELAW, A. 2011. Integrating tuberculosis and HIV services. Southern 
African Journal of Epidemiology and Infection, 26, 55-59. 
105. WHO 2008. Guidelines to the programmatic management of drug-resistant 
tuberculosis. Emergency update 2008. WHO Press: Geneva, Switzerland. 
106. ZACZEK, A., BRZOSTEK, A., WOJTASIK, A., DZIADEK, J. & SAJDUDA, A. 
2013. Genotyping of Clinical Mycobacterium tuberculosis Isolates Based on IS6110 and 
MIRU-VNTR Polymorphisms. BioMed Research International, Hindawi. 
107. ZHANG, Y. & YEW, W. W. 2009. Mechanisms of Resistance and Multi-
resistance in Tuberculosis. International Journal of Tuberculosis and Lung Disease, 13, 
1320-1330. 
108. ZUBER, B., CHAMI, M., HOUSSIN, C., DUBOCHET, J., GRIFFITHS, G. & 
DAFFE, M. 2008. Direct visualisation of the outer membrane of mycobacteria and 



















1.1.    N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) decontamination method 
Decontamination and concentration of sputum specimens using the N-acetyl-L-cysteine-sodium 
hydroxide (NALC-NaOH) method of (Kent and Kubica, 1985) is recommended as a gentle but 
effective digesting and decontaminating agent (Sharma et al., 2012).  
2g of N-Acetyl-L-Cysteine (NALC) (Sigma Aldrich, USA) was mixed with 100ml of 4% sodium 
hydroxide (NaOH) (Acechem, SA) (Appendix 1.4.1) and 100ml of sodium citrate (Acechem, SA) 
(Appendix 1.4.2). The NALC-NaOH citrate reagent was shaken well to ensure uniform mixing of 
the solution. 3-5ml of the sputum specimens were decanted into 50ml polytubes. An equal volume 
of the NALC-NaOH reagent was added to each of the tubes and vortexed briefly (10-15 seconds), 
until liquefaction of the samples. After 15 minutes, the volume was brought to 50ml by adding 
phosphate buffer (pH 6.8) (Appendix 1.4.3) to each of the tubes. Tubes were inverted briefly to 
ensure adequate mixing of solutions. The tubes were then centrifuged for 20 minutes at 3000 x g 
and the supernatant discarded. 
 
1.2.     Decontamination Solutions 
1.2.1.    4% NaOH    
80g NaOH (4%) pellets (Acechem, SA) were added to 1000ml distilled water in a 2000ml conical 
flask and allowed to dissolve and cool. NaOH is caustic and becomes quite hot in initial solution. 
Using a glass funnel, the mixture was gently poured into a 2000ml volumetric flask and volume 
made up to 2000ml. The solution was aliquoted into 200ml plastic bottles and autoclaved at 120°C 
for 15 minutes, and then stored at 4°C. 
1.2.2.   Sodium citrate 
58g Tri-sodium citrate 2H20 (Acechem, SA) was mixed with 2000ml distilled water. The solution 
was aliquoted into 200ml Duran (Schott) bottles and autoclaved at 120°C for 15 minutes, and the 
stored at 4°C.  
1.2. 3.   Phosphate buffer pH 6.8 0.067M 
Stock Alkaline Buffer 
Na2HPO4 (anhydrous) (Acechem,SA) – 94.7g 
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Distilled water – 10L 
Stock Acid Buffer 
KH2PO4 (Acechem, SA) – 90.7g 
Distilled water – 10L 
94.7g of Na2HPO4 (anhydrous) powder and 90.7g of KH2PO4 powder were added into two separate 
2L flasks. Both flasks were filled to the 2L mark with distilled water and shaken to dissolve. The 
two mixtures were then added to 16L of distilled water in a clean large bucket and mixed well. The 
pH was adjusted to 6.8 and aliquoted into 1L Duran (Schott) bottles, which were autoclaved at 
120°C for 15 minutes and stored at 4°C. 
 
1.3.     Culture in Mycobacteria Growth Indicator Tube (MGIT) 
The materials provided by the manufacturer for culture in MGIT tubes (BD BioSciences, Sparks, 
MD, USA) included BBL Mycobacteria Growth Indicator Tube (MGIT) and BACTEC
TM
MGIT 
960 supplement kit, containing BACTEC MGIT Growth Supplement and BBL MGIT
TM
PANTA 
(Polymixin, Amphotericin, Nalidixic acid, Trimethorprim, Azlocillin) antibiotic mixture (BD 
BioSciences, Sparks, MD, USA). The BACTEC MGIT growth supplement was added to a 
lyophilized vial of the BBL MGIT
TM
PANTA antibiotic mixture. Eight hundred microlitres of the 
growth supplement and PANTA mixture was then added to each MGIT tube, followed by 500µl of 
the specimen.  
1.4.      Middlebrook 7H9 broth 
9.4g of Middlebrook 7H9 base (BD, Difco laboratories, USA) powder, 4ml of (99.5%) glycerol 
(Sigma-Aldrich, USA) and 2g of Casitone (BD, Difco Laboratories, USA) were added in 1800ml 
of distilled water and mixed well. The mixture was autoclaved at 121°C for 15 minutes and cooled 
in a water bath to 56°C. 200ml of oleic acid-albumin-dextrose-catalase (OADC) (BD, USA), and 
2ml of the following antibiotics were aseptically added:  
Drug* Concentration Catalogue # 
Polymixin B 200.000 IU/L 245114 
Amphotericin B 20mg/L 245114 
Carbenicillin 100mg/L 245114 
Trimethoprim 20mg/L 245114 
*Manufactured by Sigma-Aldrich, USA 
The mixture was then dispensed into 5ml amounts in sterile free standing tubes, followed by 
storage at 4°C.  
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1.4.1. Middlebrook 7H9 Broth Buffer 
5ml of Middlebrook 7H9 broth (0.2% Glycerol, 10% OADC) was added to 45ml of phosphate 
buffer pH 6.8 (0.067M) (Appendix 1.3.). 
 
1.5. Middlebrook 7H10 agar plates 
7.6g of Middlebrook 7H10 (BD, Difco Laboratories, USA) base, 2ml of glycerol and 0.4g of 
Casitone were added to 360ml of distilled water and mixed well. The mixture was autoclaved at 
121°C for 15 minutes and cooled in a water bath to 56°C. 40ml of OADC and 1 vial of the 
specified anti-TB drug were then aseptically added and mixed well. 5ml of the resultant mixture 
was then aliquoted into pre-labelled 900mm diameter disposable quadrant petri dishes 





Abbreviations: I = Isoniazid, E = Ethambutol, R = Rifampicin, S = Streptomycin, O = Ofloxacin, N = 
Niacinamide, K = Kanamycin, E = Ethionamide, C = Capreomycin 
 









Capreomycin 10.0 µg/ml 
*Manufactured by Sigma-Aldrich, USA 
 I          E 
 R           
 S         O 
N           
 K        E 
 C         
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The empty quadrant in all plates was used for the control (no drug was added). 
 
1.6. Middlebrook 7H11 agar plates 
42g of Middlebrook 7H11 base (BD, Difco laboratories, USA) powder, 10ml of glycerol, 10ml of 
L-Asparagine monohydrate (BD, Difco Laboratories, USA) and 2g of Casitone were added to 
1800ml of distilled water and mixed well. The mixture was autoclaved at 121°C for 15 minutes 
and cooled in a water bath to 56°C. 200ml of OADC and add 2ml of PACT were aseptically added 
and mixed well. 12ml of the resultant mixture was dispensed into 650mm diameter disposable petri 
dishes (Romachem, Durban) and allowed to set, followed by storage at 4°C.  
 
1.7.    Culture Confirmation Tests 
1.7.1.   Nitrate Test 
Sterile tubes were labelled with isolate numbers and 500µl of nitrate broth was aliquoted into each 
tube. Using a sterile quadloop, a loopful of culture was scraped off the Middlebrook 7H11 agar 
plate (1% glycerol, 10% OADC) and suspended into the tubes containing nitrate broth. Tubes were 
incubated at 37°C for 2 hours. Following incubation, 1 drop of concentrated hydrochloric acid 
(HCl) (Merck, SA), followed by 2 drops of 0.2% sulfanilimide (Sigma-Aldrich, USA) (nitrile 1) 
solution, and 2 drops of 0.1% N-(naphthyl)-ethylenediamine dihydrochloride (Sigma-Aldrich, 
USA) (nitrite 2) solution was added to all tubes. Tubes were observed for a colour change, any 
shade of pink indicated a positive result (Isenberg, 2004a). H37Rv laboratory strain was used as a 
positive control and a tube containing no culture was used as a negative control. 
1.7.2.   Niacin Test 
A drop of cyanogen bromide (Sigma-Aldrich, USA) was added onto a lawn of confluent growth 
followed by a drop of aniline (Sigma-Aldrich, USA) on top of the cyanogen bromide. Plates were 
left for 5 minutes and thereafter observed for the presence of a colour change, a shade of yellow 
indicated a positive result (Isenberg, 2004a). H37Rv was used as a positive control and un-






2.1.    DNA Isolation 
MTB colonies were scraped off LJ slants using a sterile swab and suspended into 2ml micro-
centrifuge tubes (Eppendorf) containing 500µl of sterile distilled water. The bacteria were heat 
killed at 80˚C in a thermomixer comfort (Merck, SA)  for 30 minutes following which 70µl of 10% 
Sodium Dodecyl Sulfate (SDS) (Sigma-Aldrich, USA) (Appendix 2.3.4) solution and 50µl of 
proteinase K (Roche Diagnostics, Manneheim, Germany) (Appendix 2.3.3) of concentration 
10mg/ml were added to each tube. The tubes were then incubated  in a thermomixer comfort 
(Merck, SA) at 60˚C for 1 hour. The 5M Sodium chloride (NaCl) (Sigma-Aldrich, USA) 
(Appendix 2.3.5) and CTAB-NaCl (Sigma-Aldrich, USA) (Appendix 2.3.6) solutions were pre-
warmed at 60˚C and 100µl of each solution was added to each tube an mixed thoroughly by 
inverting the tubes a few times. 
The tubes were then incubated at 60˚C for 15 minutes and 700µl of Chloroform (Sigma-Aldrich, 
USA): Isoamyl alcohol (Sigma-Aldrich, USA) (24:1) (Appendix 2.3.7) solution was added to each 
tube and inverted several times until the contents turned milky. Tubes were centrifuged for 10 
minutes at 12000 rpm. The upper aqueous supernatant was transferred to 2ml micro-centrifuge 
tubes (Eppendorf) which contained 700µl of Isopropanol (Sigma-Aldrich, USA). Tubes were 
inverted several times and placed in a -20˚C freezer for 30 minutes, followed by centrifugation for 
10 minutes at room temperature at 12000 rpm. The isopropanol was discarded and the pellet was 
washed with 80% ethanol (Merck, SA) (Appendix 2.3.8) and centrifuged for 10 minutes at 12000 
rpm. The ethanol was discarded and the pellets were left to dry for 10 minutes at room 
temperature. 55µl of 1xTE buffer (Appendix 2.3.2) was added to each pellet and stored at 4˚C 
overnight or until further use. A 5µl volume of each DNA sample was electrophoresed on a 1% 
agarose gel to estimate DNA concentration. 
 
2.2.   Gel Electrophoresis 
A 1% agarose gel (Appendix 2.3.9) was made using 1xTris-Borate-EDTA (TBE) buffer (Appendix 
2.3.11). The agarose (Lonza, USA) was dissolved in 1xTBE buffer by heating in a microwave. The 
solution was allowed to cool and poured into a casting tray, which was taped up around the edges, 
with a 20 well comb. The agarose solution was allowed to set at room temperature. Once the gel 
had solidified the tape and comb were removed and the casting tray, containing the gel, was placed 
into an electrophoresis tank (Hoefer) containing 1xTBE buffer. A 3-5µl volume of sample loading 
dye (Appendix 2.3.12) was added to a piece of parafilm for each DNA sample and 2µl of each 
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DNA sample was mixed with the dye and loaded into a well of the gel. Electrophoresis was 
performed at 100 volts (V) for 30-45 minutes. 
 
2.3.   DNA Extraction Solutions 
2.3.1.   10X TE Buffer 
1,21g of trizma base was dissolved in 80ml of autoclaved distilled water. The pH was adjusted to 8 
using concentrated hydrochloric acid (HCl) (Merck, SA), followed by the addition of EDTA. The 
solution was then made up to a final volume of 100ml using autoclaved distilled water. 
2.3.2. 1X TE Buffer 
10ml of 10xTE Buffer was dissolved in 90ml of distilled water and stored at room temperature. 
2.3.3.   Proteinase K  
482µl of PCR grade water (Roche Diagnostics, USA) was added to 518µl of PCR grade 
recombinant proteinase K and stored at 4°C. 
2.3.4.   10% Sodium Dodecyl Sulfate (SDS)  
1g of SDS powder was dissolved in 10ml of distilled water. 
2.3.5.   5M Sodium Chloride (NaCl)  
14.6g of NaCl powder was dissolved in 50ml of autoclaved distilled water. 
2.3.6.   CTAB-NaCl Solution 
4.1g of NaCl and 10g of CTAB were dissolved in 100ml of distilled water. The solution was 
heated to 65°C, until powders were completely dissolved. 
2.3.7.   Chloroform: Isoamyl alcohol (24:1) 
1ml of isoamyl alcohol was added to 24ml of chloroform and mixed well. 
2.3.8.   80% ethanol 
80ml of ethanol were added to 20ml of distilled water. 
 2.3.9.   1% agarose gel 
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1.4g of agarose powder was added to a flask containing 140ml 1xTBE buffer. The mixture was 
boiled using a microwave, until the powder dissolved. 
2.3.10.   10X TBE Buffer 
108g of trizma base, 55g of boric acid (Sigma-Aldrich, USA) and 9.3g of EDTA were dissolved in 
800ml of autoclaved distilled water. After dissolution the volume was made up to 1000ml with 
autoclaved distilled water. 
2.3.11.   1X TBE Buffer 
100ml of 10xTBE buffer were added to 900ml of autoclaved distilled water and stored at room 
temperature. 
2.3.12.   Loading Dye – 1% Double Dye 
1g of bromophenol blue (Sigma-Aldrich, USA) and 1g of xylene cyanole (Sigma-Aldrich, USA) 
were added to 100ml of autoclaved distilled water. This is the 1% double dye. 
50ml of Loading Dye from 1% Double Dye Stock: 
5ml of 10xTBE buffer, 25ml of glycerol, and 5ml of 1% double dye were added to a 50ml tube and 
















Appendix 3  
IS6110 is an insertion element that is found exclusively within the Mycobacterium tuberculosis 
complex (MTBC). A benefit of this exclusivity is that IS6110 has become an important diagnostic 
tool in the differentiation of MTBC species from other mycobacteria. The element’s presence in 
multiple copies, and at differing locations in the genome, has provided an excellent method by 
which strains can be genotyped; and because of these characteristics, IS6110 has been used 
extensively for epidemiological studies (Coros et al., 2008).  
3.1. Restriction 
Restriction digestion is the process of cutting DNA molecules into smaller pieces with special 
enzymes called restriction endonucleases. PvuII restriction endonuclease was used for restriction 
digestion, which recognizes the double-stranded DNA sequence 5’-CAGCTG-3’ and cleaves after 
the G-3’ end. Proteus vulgaris is the genomic source for PvuII. It is the most commonly used 
restriction enzyme and it creates blunt ends which can be ligated into a blunt cloning site easily 
(Yaich et al., 1992). 
 
3.2. Southern Blotting 
The membrane was cut to the size of 15x20cm ad placed into a glass container containing distilled 
water. This was followed by a 5 minute washing step of the membrane in 10xSSC solution 
(Appendix 3.5.4) on an orbital shaker at room temperature. The vacuum blotting unit (Vacugene) 
was set up by placing the porous support (Amersham, Buckinghamshire, UK) onto the blotting unit 
correctly, followed by placing the membrane on top. The plastic mask (Amersham, 
Buckinghamshire, UK) was then aligned accordingly over the edges of the membrane. The gel was 
removed from the electrophoresis tank and gently slid onto the membrane. The vacuum pump was 
started and once it reached 55cm bar a 1:100 HCl solution (Appendix 3.5.8) was poured over the 
gel and the vacuum applied for 20 minutes. The HCl solution was removed by tilting the blotting 
unit and aspirated using a suction device. The next solution called soak 1 (Appendix 3.5.1) was 
poured over the gel and the vacuum applied again for 20 minutes. The aspiration step was repeated 
as previously and the soak 2 solution (Appendix 3.5.2) was poured over the gel followed by 
application of the vacuum for 20 minutes and aspiration. 10xSSC was poured over the gel, the 
vacuum was increased to 65cm bar and applied for 1½ hours. At all times the gel was completely 
covered with the appropriate solution used. On completion of blotting, the last solution was 





The membrane was pre-hybridised using 25-30ml of hybridisation buffer (Amersham, 
Buckinghamshire, UK) (Appendix 3.5.7), rotating for 30 minutes in a hybridisation oven (Stuart) 
set at 42°C. In a micro-centrifuge tube 10µl of the probe was mixed with 5µl of sterile distilled 
water, boiled for 5 minutes and placed on ice for 10 minutes. Equal volumes of DNA labelling 
reagent (Amersham, Buckinghamshire, UK) and gluteraldehyde (Amersham, Buckinghamshire, 
UK) were added to the probe mixture and incubated in a water bath at 37°C for 10-15 minutes. 
Hybridisation buffer covering the membrane was mixed with the probe and this mixture was then 
poured back into the hybridisation bottle containing the membrane. The hybridisation took place 
overnight at 42°C in a hybridisation oven on a bottle rotisserie. 
The hybridisation buffer was discarded the next day and the membrane was rinsed with primary 
wash buffer (Appendix 3.5.5) which was discarded. Another volume of primary wash buffer was 
added to the membrane followed by incubation for 30 minutes at 42°C. The membrane was rinsed 
with 2xSSC solution (Appendix 3.5.6) and transferred to a glass container. Two 5 minute washes 
with 2xSSC were applied at room temperature on an orbital shaker (Stuart). The final solution was 
discarded and the membrane was transferred to a plastic container. 
 
3.4. Detection 
This was performed in the darkroom. For detection of the hybridised DNA, the membrane was 
submerged for 2 minutes in 8ml of ECL detection solution (Amersham, Buckinghamshire, UK). 
The membrane was drained and wrapped in cling wrap and wiped with tissue to remove bubbles. It 
was then placed into a hypercassette (Amersham, Buckinghamshire, UK), followed by exposure of 
a hyperfilm (Amersham, Buckinghamshire, UK) to it for 20 minutes. The hyperfilm was removed 
and placed into developer (Agfa-Gevaert, Belgium) until all bands appeared and then placed into 
fixer (Afga-Gevaert, Belgium) until the background was clear. It was then rinsed with tap water 
and hung to dry.  
 
3.5. IS6110 Restriction Fragment Length Polymorphism (RFLP) Solutions 
 3.5.1.   Soak 1 
20g of NaOH and 87.66g of NaCl were added to 800ml of autoclaved distilled water. After 
dissolution the volume was made up to 1000ml with autoclaved distilled water. 
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3.5.2.   Soak 2 
62.6g of trizma base, 87.67g of NaCl, and 40ml of HCl were added to 800ml of autoclaved 
distilled water. The pH was adjusted to 7.2 using concentrated HCl, and then the volume was made 
up to 1000ml with autoclaved distilled water. 
3.5.3.   20X SSC 
175g of NaCl and 88g of sodium citrate was added to 800ml of autoclaved distilled water. The pH 
was adjusted to 7.0 using concentrated HCl, and then the volume was made up to 1000ml with 
autoclaved distilled water. 
3.5.4.   10X SSC 
500ml of 20xSSC was added to 500ml of autoclaved distilled water and stored at room 
temperature. 
3.5.5.   Primary Wash Buffer 
360g of urea (Sigam-Aldrich, USA), 25ml of 20xSSC, and 4g of SDS were added to 600ml of 
autoclaved distilled water. After dissolution the volume was made up to 1000ml with autoclaved 
distilled water. 
3.5.6.   Secondary Wash Buffer (2X SSC) 
20ml of 20xSSC was added to 400ml of autoclaved distilled water and stored at room temperature. 
3.5.7.   Hybridization Buffer 
30ml of 5M NaCl, and 15g of blocking reagent (Amersham, UK) were added to 270ml of 
hybridization buffer (Amersham, UK). The mixture was heated at 60°C, with continuous stirring, 
to enable blocking agent to dissolve. The hybridization buffer was then aliquoted into 50ml falcon 
tubes and stored at -20°C. 
3.5.8.   1:100 HCl 








For hybridisation, 20µl of each PCR product was diluted in 150µl 2xSSPE 0.1% SDS (Appendix 
4.2.4). The diluted PCR products were heat-denatured for 10 minutes at 99°C and thereafter cooled 
on ice. The membrane (Ocimum Biosolutions, India) was washed for 5 minutes at 60°C in 250ml 
of 2xSSPE 0.1% SDS. The membrane and a support cushion (Ocimum Biosoultions, India) were 
placed onto the mini-blotter, so that the slots were perpendicular to the applied oligonucleotides 
present on the membrane. The residual fluid in the slots of the mini-blotter was removed by 
aspiration. The diluted PCR products were pipette into the slots in such a way that the mini-blotter 
channels were perpendicular to the row of the oligonucleotides. Hybridisation was done for 1 hour 
at 60°C. Samples were removed by aspiration and plastic forceps were used to remove the 
membrane from the mini-blotter and to place this into a plastic container. 
The membrane was washed twice using 250ml of 2xSSPE 0.5% SDS (Appendix 4.2.5) for 10 
minutes at 60°C. The membrane was allowed to cool in a plastic container to prevent inactivation 
of the peroxidise that followed. Streptavidin-peroxidase conjugate (Roche Diagnostics, Mannheim, 
Germany) was added to 20ml of 2xSSPE 0.5% SDS. The membrane was incubated in this solution 
for 55 minutes at 42°C in its plastic container. The membrane was washed twice using 250ml of 
2xSSPE 0.5% SDS for 10 minutes at 42°C and thereafter washed twice using 250ml of 2xSSPE 
(Appendix 4.2.6) for 5 minutes at room temperature. 
 
4.2. Spoligoytping Solutions  
4.2.1.   20xSSPE Solution 
35.6g of 0.2M Na2HPO4.2H2O (Sigma-Aldrich, USA), 210.24g of 3.6M NaCl, and 20mM EDTA 
were added to 800ml of distilled water. The pH was adjusted to 7.4 using 4M NaOH and the final 
volume made up to 1000ml using autoclaved distilled water. 
4.2.2.   0.5M EDTA 
93.05g of EDTA powder was added to 450ml of distilled water. The pH was adjusted to 8 using 
NaOH and the final volume made up to 500ml using autoclaved distilled water. 
4.2.3.   10% SDS solution 
10g of SDS was dissolved in 100 ml of distilled water. 
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4.2.4.   2xSSPE 0.1% SDS 
26ml of 20xSSPE and 2.6ml of 10% SDS were added to 231.4ml of distilled water. 
4.2.5.   2xSSPE 0.5% SDS 
102ml of 20xSSPE and 51ml of 10% SDS were added to 867ml of distilled water. 
4.2.6.   2xSSPE 
50ml of 20xSSPE was added to 450ml of distilled water. 
4.2.7.   1% SDS 
40ml of 10% SDS was added to 360ml of distilled water. 
4.2.8.   20mM EDTA 



















We are doing research on the hospital acquired transmission of TB within ward 2 (female ward) 
and wards 3 and 4 (male wards) at the FOSA TB Hospital. FOSA TB hospital is a dedicated 
facility that houses MDR/XDR TB patients. Infection with one strain of Mycobacterium 
tuberculosis does not protect against infection with a new strain from another contact, so the study 
aims to study the degree of transmission of TB within the designated wards.   
We have explained the study to you and would appreciate your participation. The study as we had 
mentioned requires us to take sputum specimens from you upon commencement of the study, at 6 
weeks and after 3 months. You have a choice to participate or decline participation in this study. If 
you decline participation, the provision of health care will not be any different as compared to 
those that agree to participate. 
If you agree to participate please sign this form. 
I, ____________________________________ (Name of Patient) understand the nature of the 
research project and agree to be part of this study. I also understand that it is my right to withdraw 
from this study at any time, even after signing this document. 
Signature of Patient: ________________________ 
Witnesses: ________________________ (Name & Signature) 
If you have any queries at any time you may contact the following: 
Prashini  Moodley 
Chief Specialist, Infection Prevention and Control 
KZN Department of Health and 
Nelson R Mandela School of Medicine 
University of KwaZulu-Natal 
719 Umbilo Road  
Congella 
4013 









Infection, Prevention and Control Department 
Nelson R Mandela School of Medicine 
University of KwaZulu-Natal 
18 Chestnut Road 
Glenwoood, 
Durban, South Africa 
Mobile: 27-84-229-9377 
Email: lungilemsizi4@gmail.com  
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Ward 3 and 4 floor plan (Male ward) 
 
